CA2383776A1 - Method for generating immune-compatible cells and tissues using nuclear transfer techniques - Google Patents
Method for generating immune-compatible cells and tissues using nuclear transfer techniques Download PDFInfo
- Publication number
- CA2383776A1 CA2383776A1 CA002383776A CA2383776A CA2383776A1 CA 2383776 A1 CA2383776 A1 CA 2383776A1 CA 002383776 A CA002383776 A CA 002383776A CA 2383776 A CA2383776 A CA 2383776A CA 2383776 A1 CA2383776 A1 CA 2383776A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- cells
- animal
- teratoma
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 98
- 238000012546 transfer Methods 0.000 title claims abstract description 33
- 238000002054 transplantation Methods 0.000 claims abstract description 43
- 210000004027 cell Anatomy 0.000 claims description 229
- 210000001519 tissue Anatomy 0.000 claims description 143
- 241001465754 Metazoa Species 0.000 claims description 66
- 206010043276 Teratoma Diseases 0.000 claims description 59
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 230000000735 allogeneic effect Effects 0.000 claims description 34
- 239000000427 antigen Substances 0.000 claims description 30
- 108091007433 antigens Proteins 0.000 claims description 30
- 102000036639 antigens Human genes 0.000 claims description 30
- 210000000130 stem cell Anatomy 0.000 claims description 30
- 241000283690 Bos taurus Species 0.000 claims description 24
- 241000124008 Mammalia Species 0.000 claims description 23
- 210000001161 mammalian embryo Anatomy 0.000 claims description 22
- 108020005196 Mitochondrial DNA Proteins 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 210000000287 oocyte Anatomy 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 16
- 210000003734 kidney Anatomy 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 15
- 210000002027 skeletal muscle Anatomy 0.000 claims description 14
- 108091093105 Nuclear DNA Proteins 0.000 claims description 13
- 238000010171 animal model Methods 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 11
- 210000003491 skin Anatomy 0.000 claims description 11
- 210000001654 germ layer Anatomy 0.000 claims description 10
- 210000004698 lymphocyte Anatomy 0.000 claims description 10
- 210000004165 myocardium Anatomy 0.000 claims description 10
- 241000894007 species Species 0.000 claims description 10
- 210000002257 embryonic structure Anatomy 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 210000002460 smooth muscle Anatomy 0.000 claims description 8
- 210000002950 fibroblast Anatomy 0.000 claims description 7
- 108700008625 Reporter Genes Proteins 0.000 claims description 6
- 230000024245 cell differentiation Effects 0.000 claims description 6
- 210000003195 fascia Anatomy 0.000 claims description 6
- 230000001010 compromised effect Effects 0.000 claims description 5
- 210000003754 fetus Anatomy 0.000 claims description 5
- 210000000987 immune system Anatomy 0.000 claims description 4
- 230000004077 genetic alteration Effects 0.000 claims description 3
- 231100000118 genetic alteration Toxicity 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000011580 nude mouse model Methods 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 108060001084 Luciferase Proteins 0.000 claims description 2
- 239000005089 Luciferase Substances 0.000 claims description 2
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 2
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 230000002438 mitochondrial effect Effects 0.000 claims 5
- 238000003556 assay Methods 0.000 claims 1
- 210000001082 somatic cell Anatomy 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- 238000010367 cloning Methods 0.000 abstract description 15
- 108700019146 Transgenes Proteins 0.000 abstract description 3
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract 1
- 210000003470 mitochondria Anatomy 0.000 description 95
- 108020004414 DNA Proteins 0.000 description 35
- 210000004940 nucleus Anatomy 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- 210000000056 organ Anatomy 0.000 description 14
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 206010052779 Transplant rejections Diseases 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 8
- 241000283707 Capra Species 0.000 description 7
- 210000000845 cartilage Anatomy 0.000 description 7
- 239000007943 implant Substances 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 6
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 210000004413 cardiac myocyte Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000010899 nucleation Methods 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 238000011579 SCID mouse model Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000013020 embryo development Effects 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000001744 histochemical effect Effects 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 101100264174 Mus musculus Xiap gene Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 description 3
- 108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 102000005937 Tropomyosin Human genes 0.000 description 3
- 108010030743 Tropomyosin Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000011712 cell development Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 210000005084 renal tissue Anatomy 0.000 description 3
- 210000002363 skeletal muscle cell Anatomy 0.000 description 3
- QCHQVPPBLFSODM-MZWCVTMLSA-N Ac-Asp-Lys-Ala-Thr-Ile-Gly-Phe-Glu-Val-Gln-Glu-Glu Chemical compound OC(=O)C[C@H](NC(C)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CC1=CC=CC=C1 QCHQVPPBLFSODM-MZWCVTMLSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 206010068051 Chimerism Diseases 0.000 description 2
- 102100027152 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial Human genes 0.000 description 2
- 101710205862 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial Proteins 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 108700005089 MHC Class I Genes Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 102000013394 Troponin I Human genes 0.000 description 2
- 108010065729 Troponin I Proteins 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000003367 anti-collagen effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 238000010231 histologic analysis Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000003716 rejuvenation Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000009772 tissue formation Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108010030844 2-methylcitrate synthase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010004659 Biliary cirrhosis Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 101150087323 COI gene Proteins 0.000 description 1
- 240000002317 Camassia leichtlinii Species 0.000 description 1
- 235000000459 Camassia leichtlinii Nutrition 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 108010071536 Citrate (Si)-synthase Proteins 0.000 description 1
- 102000006732 Citrate synthase Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000009093 Dihydrolipoyllysine-residue acetyltransferase Human genes 0.000 description 1
- 108010073112 Dihydrolipoyllysine-residue acetyltransferase Proteins 0.000 description 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
- 206010052805 Drug tolerance decreased Diseases 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000000435 Heart Rupture Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 101150118256 M3 gene Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 108010086428 NADH Dehydrogenase Proteins 0.000 description 1
- 102000006746 NADH Dehydrogenase Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102100040557 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical group CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003409 anti-rejection Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000023715 cellular developmental process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 210000001771 cumulus cell Anatomy 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001162 elastic cartilage Anatomy 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229960000469 flunixin meglumine Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- -1 imoran Chemical compound 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000004242 micellar liquid chromatography Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920005594 polymer fiber Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 210000003742 purkinje fiber Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000005487 simulated microgravity Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/04—Cells produced using nuclear transfer
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention relates to methods for making immune compatible tissues and cells for the purpose of transplantation and tissue engineering, using the techniques of nuclear transfer and cloning. Also encompassed are methods for determining the effect on immune compatibility of expressed transgenes and other genetic manipulations of the engineered cells and tissues.
Description
METHOD FOR GENERATING IMMUNE-COMPATIBLE CELLS AND
TISSUES USING NUCLEAR TRANSFER TECHNIQUES
This application claims the benefit of U.S. Provisional Patent Application No.
60/152,354 filed September 7, 1999 and U.S. Provisional Patent Application No.
60/155,107 filed September 22, 1999.
Field of Invention The present invention combines the fields of cloning, developmental biology and tissue engineering to devise immune compatible tissues and cells for the purpose of transplantation. In addition, the invention discloses methods of generating therapeutic cells and tissues for transplantation using nuclear transfer techniques, and methods of verifying or evaluating the immune compatibility of such tissues.
Background of Invention The past decade has been characterized by significant advances in the science of cloning, and has witnessed the birth of a cloned sheep, i.e. "Dolly"
(Roslin Bio-Med), a trio of cloned goats named "Mira" (Genzyme Transgenics) and over a dozen cloned cattle (ACT). The technology which enables cloning has also advanced such that a mammal may now be cloned using the nucleus from an adult, differentiated cell, which scientists now know undergoes "reprogramming" when it is introduced into an enucleated oocyte. See U.S. Patent 5,945,577, herein incorporated by reference in its entirety.
The fact that an embryo and embryonic stem cells may be generated using the nucleus from an adult differentiated cell has exciting implications for the fields of organ, cell and tissue transplantation. There are currently thousands of patients waiting for a suitable organ donor, and face problems of both availability and incompatibility in their wait for a transplant. If embryonic stem cells generated from the nucleus of a cell taken from a patient in need of a transplant could be made and induced to differentiate into the cell type required in the transplant, then the problem of transplantation rejection and the dangers of immunosuppressive drugs could be precluded.
Embryonic stem cells have been induced to develop into cells from the three different germ layers. For instance, Anderson et al. demonstrated that inner cell masses (ICM) and embryonic discs from bovine and porcine blastocysts will develop into teratomas containing differentiated cell types from ectodermal, mesodermal and endodermal origins when transplanted under the kidney capsule of athymic mice.
Animal Repro. Sci. 45: 231-240 (1996). Furthermore, the developmental signals that trigger cell differentiation are beginning to be deciphered. For instance, Gourdie et al. demonstrated the differentiation of embryonic myocytes into impulse-conducting Purkinje fiber cells. Proc Natl Acad Sci USA 95: 6815-6818 (June, 1998). Further, researchers at the University of Medicine and Dentistry of New Jersey (UMDNJ) have recently reported the transformation of bone marrow cells into nerve cells (Washington Post, August 15, 2000, p. A6). Thus, it should be possible to isolate differentiated cells from embryonic stem cells or teratomas, and induce their differentiation into particular cell types for use in transplantation.
In addition, by using techniques evolving in the field of tissue engineering, tissues and organs could be designed from the differentiated cells, which could be used for transplantation. For instance, Shinoka et al. have designed viable pulmonary artery autografts by seeding cells in culture onto synthetic biodegradble (polyglactinlpolglycolic acid) tubular scaffolds. I Thorac Cardiovasc. Sure.
115:
536-546 (1998). Zund et al. demonstrated that seeding of human fibroblasts followed by endothelial cells on resorbable mesh is helpful for creation of human tissues such as vessels or cardiac valves. Eur J Cardic-Thorac. Surg. 13: 160-(1998). Freed et al. have shown that culturing cells under conditions of simulated microgravity is advantageous for the engineering of cartilage and heart tissue. In Vitro Cell Dev. Bid. --Animal 33: 38 1-385 (May, 1997).
However, the fields relating to cell development and differentiation, and tissue engineering have deficiencies. For instance, the teratomas created by Anderson et al.
were created from naturally-formed embryos. Thus, the genotype of the embryos will be unique to the individual embryos. Such cells are not appropriate for transplantation, because they would still induce transplant rejection just as any allogeneic tissue when transplanted into a donor animal. Most autograft tissue engineering studies, in contrast, have been performed using cells from the actual recipient animal. Such a technique will not provide suitable transplant organs to those patients whose cells or organs are deficient, i.e., perhaps for lack of gene expression, or due to expression of a mutant gene. Moreover, for a patient whose organ has literally shut down, it will not be possible to engineer a new organ from the patient's own cells. Thus, there are many deficiencies to be overcome in applying the concepts of cellular differentiation and development and tissue engineering to the treatment of transplant patients.
Summary of Invention The present invention addresses the uncertainties still to be overcome in the use of engineered cells and tissues for transplantation. The invention discloses methods of engineering cloned, immune compatible, developmentally differentiated cells into tissues for transplantation, and methods of using such tissues to treat a patient in need of a transplant. In particular, such tissues may be designed to express a therapeutic protein. Because the tissues and cells for transplantation are all generated from the same original donor cell through nuclear transfer, all the cells of the engineered tissue will express the heterologous gene of interest. The methods of the invention therefore additionally provide an invaluable alternative to tissue-targeted gene therapy.
The present invention also provides methods for determining whether particular genetically engineered cells will provide immune compatible organs for transplantation. For instance, the present invention discloses methods of evaluating cloned cells for mitochondria) compatibility, and in particular, transgenic, developmentally differentiated cells, for immune compatibility in an animal model.
Such evaluations will provide important information regarding the suitability of therapeutic tissues in transplantation, and will provide the foundation for controlling these parameters in order to provide immune compatible tissues.
Detailed Description The present invention is directed to methods of producing of immune compatible tissues using cloning technology. The cells and engineered tissues produced by the disclosed methods are also encompassed in the present invention, as are the stable grafts produced by transplantation of the engineered tissues. A
stable graft is defined as a graft that does not illicit an immune response or rejection when transplanted into a nuclear donor, or at least provides a substantial improvement in avoiding graft rejection over non-cloned control transplanted tissue.
Because cloned cells generated by nuclear transfer are not completely identical with the donor cell or animal, e.g., they typically lack the mitochondria) DNA
of the donor cell and gain the mitochondria) DNA of the recipient enucleated oocyte or other cell and typically are not produced in an in vivo environment that will perfectly mimic conditions present during embryogenesis, the question is raised as to whether such cells will be entirely immune-compatible when they are transplanted back into the donor animal.
For instance, it has been demonstrated that mitochondria) peptides in mice, e.g., the ND 1 peptide from the amino terminus of NADH dehydrogenase and the MiHA peptide encoded by the amino terminus of the COI gene, are presented at the cell surface by non-classical MHC class I molecules, e.g., H-2M3a, in combination with beta-2-microglobulin (Vyas et al., 1992, "Biochemical specificity of H-2M3a . .
.," J. Immunol. 149(11):3605-11; Morse et al., 1996, "The COI mitochondria) gene encodes a minor histocompatibility antigen presented by H2-M3," J. Immunol.
156(9): 3301-7). It has also been shown that allelic variation at a single residue in the ND 1 peptide renders cells displaying foreign alleles susceptible to lysis by specific cytotoxic T cells (Loveland et al. 1990. 60(6): 971-80). A similar system has been identified in rats, although the mitochondria) peptide which is responsible for histocompatibility in the rat is not the same as the allelic ND1 peptide from mice (Davies et al., 1991, "Generation of T cells with lytic specificity for atypical antigens.
I. A mitochondria) antigen in the rat," J. Exp. Med. 173: 823-32).
Thus, mitochondria) peptides displayed at the cell surface can serve as histocompatibiliy antigens, seeing as two separate systems have been identified in mice and rats, respectively. There is no reason to believe that similar systems would not be present in other mammals. Therefore, foreign mitochondria would be expected to result in the rejection of therapeutic tissue generated by nuclear transfer technology. Instead, using the methods of the present invention, the present inventors have surprisingly found in performing the methods of the present invention that nuclear transfer generated cells having allogeneic mitochondria are not rejected when transplanted into the nuclear donor.
Despite the fact that cloned tissues having allogeneic mitochondria were not rejected after transplant, the question of transplant compatibility becomes even more relevant when such cells are transfected with a transgene or undergo some other genetic manipulation in order to modify, supplement or bolster the function of the transplanted tissue. Accordingly, the present invention provides methods and animal models for testing the immune compatibility of cloned cells or tissues in an animal model, and for enhancing the immune compatibility of such cells or tissues as needed.
Generally, such methods comprise:
I S a. obtaining a cell from a donor animal;
b. transferring the nucleus from said cell into a recipient oocyte or other suitable recipient cell to generate an embryo and optionally introducing a therapeutic heterologous DNA;
c. isolating an embryonic disc, inner cell mass, and/or stem cell from said embryo;
d. injecting said disc and/or stem cell into said donor animal at the same time as control embryonic disc and/or stem cell; and e. examining the injection sites for teratoma formation, and signs of subsequent rejection.
For the purposes of the present invention, a teratoma is defined as a group of differentiated cells containing derivatives of mesoderm, endoderm, or ectoderm resulting from totipotent cells. A control embryonic disc, inner cell mass, or stem cell is one which was not generated using a donor cell from the test animal (allogeneic or xenogeneic nuclear DNA), and therefore, the teratoma thus generated from such disc or cell is expected to be rejected in the donor animal, or alternatively, may never develop at all. Teratomas generated using a nucleus from the donor animal (isogenic) and an allogeneic recipient oocyte or other suitable recipient cell would also be expected to be rejected when used in transplantation due to presentation of mitochondria) alleles as histocompatibility antigens. Thus, the fact that such therapeutic tissues do not lead to transplant rejection is truly surprising indeed.
Donor and control embryonic discs, inner cell mass, and/or stem cells are generally injected intramuscularly, introduced under the renal capsule, subcutaneously or into the paralumbar fascia. Where a teratoma is formed, it is removed and examined for the presence of germ layers, which may further be separated for the purpose of detecting or isolating specific cell types. While teratoma formation may give an initial indication of immune compatibility, specific cell types may be generated and re-introduced into the donor animal to further test immune compatibility, particularly where the transfected heterologous gene is expressed from a cell-type specific promoter. Given that the cloned tissues of the present invention having allogeneic mitochondria were not rejected, this system is ideal for testing the affect of a transgene on tissue compatibility whereby the cell from said donor animal is transfected with a heterologous gene prior to nuclear transfer.
Generally, the methods of the invention may be performed using any cell from the donor animal. Suitable cells include by way of example immune cells such as B
cells, T cells, dendritic cells, skin cells such as keratinocytes, epithelial cells, chondrocytes, cumulus cells, neural cells, cardiac cells, esophagial cells, primordial germ cells, cells of various organs including the liver, stomach, intestines, lung, kidneys, etc. In general, the most appropriate cells are easily propagatable in tissue culture and can be easily transfected. Preferably, cell types for transfecting heterologous DNA and performing nuclear transfer are fibroblasts.
The animal model may be any animal suitable for generating teratomas and studying immune compatibility. A preferred animal is an ungulate, and more preferred is a bovine. Alternatively, the animal may be a non-human primate, e.g., a baboon or cynomolgus monkey. Large animals are preferred because they may give rise to larger teratomas, thereby providing more cells for immunological evaluation and for transplantation. Suitable animals include by way of example pigs, dogs, horses, buffalo and goats.
TISSUES USING NUCLEAR TRANSFER TECHNIQUES
This application claims the benefit of U.S. Provisional Patent Application No.
60/152,354 filed September 7, 1999 and U.S. Provisional Patent Application No.
60/155,107 filed September 22, 1999.
Field of Invention The present invention combines the fields of cloning, developmental biology and tissue engineering to devise immune compatible tissues and cells for the purpose of transplantation. In addition, the invention discloses methods of generating therapeutic cells and tissues for transplantation using nuclear transfer techniques, and methods of verifying or evaluating the immune compatibility of such tissues.
Background of Invention The past decade has been characterized by significant advances in the science of cloning, and has witnessed the birth of a cloned sheep, i.e. "Dolly"
(Roslin Bio-Med), a trio of cloned goats named "Mira" (Genzyme Transgenics) and over a dozen cloned cattle (ACT). The technology which enables cloning has also advanced such that a mammal may now be cloned using the nucleus from an adult, differentiated cell, which scientists now know undergoes "reprogramming" when it is introduced into an enucleated oocyte. See U.S. Patent 5,945,577, herein incorporated by reference in its entirety.
The fact that an embryo and embryonic stem cells may be generated using the nucleus from an adult differentiated cell has exciting implications for the fields of organ, cell and tissue transplantation. There are currently thousands of patients waiting for a suitable organ donor, and face problems of both availability and incompatibility in their wait for a transplant. If embryonic stem cells generated from the nucleus of a cell taken from a patient in need of a transplant could be made and induced to differentiate into the cell type required in the transplant, then the problem of transplantation rejection and the dangers of immunosuppressive drugs could be precluded.
Embryonic stem cells have been induced to develop into cells from the three different germ layers. For instance, Anderson et al. demonstrated that inner cell masses (ICM) and embryonic discs from bovine and porcine blastocysts will develop into teratomas containing differentiated cell types from ectodermal, mesodermal and endodermal origins when transplanted under the kidney capsule of athymic mice.
Animal Repro. Sci. 45: 231-240 (1996). Furthermore, the developmental signals that trigger cell differentiation are beginning to be deciphered. For instance, Gourdie et al. demonstrated the differentiation of embryonic myocytes into impulse-conducting Purkinje fiber cells. Proc Natl Acad Sci USA 95: 6815-6818 (June, 1998). Further, researchers at the University of Medicine and Dentistry of New Jersey (UMDNJ) have recently reported the transformation of bone marrow cells into nerve cells (Washington Post, August 15, 2000, p. A6). Thus, it should be possible to isolate differentiated cells from embryonic stem cells or teratomas, and induce their differentiation into particular cell types for use in transplantation.
In addition, by using techniques evolving in the field of tissue engineering, tissues and organs could be designed from the differentiated cells, which could be used for transplantation. For instance, Shinoka et al. have designed viable pulmonary artery autografts by seeding cells in culture onto synthetic biodegradble (polyglactinlpolglycolic acid) tubular scaffolds. I Thorac Cardiovasc. Sure.
115:
536-546 (1998). Zund et al. demonstrated that seeding of human fibroblasts followed by endothelial cells on resorbable mesh is helpful for creation of human tissues such as vessels or cardiac valves. Eur J Cardic-Thorac. Surg. 13: 160-(1998). Freed et al. have shown that culturing cells under conditions of simulated microgravity is advantageous for the engineering of cartilage and heart tissue. In Vitro Cell Dev. Bid. --Animal 33: 38 1-385 (May, 1997).
However, the fields relating to cell development and differentiation, and tissue engineering have deficiencies. For instance, the teratomas created by Anderson et al.
were created from naturally-formed embryos. Thus, the genotype of the embryos will be unique to the individual embryos. Such cells are not appropriate for transplantation, because they would still induce transplant rejection just as any allogeneic tissue when transplanted into a donor animal. Most autograft tissue engineering studies, in contrast, have been performed using cells from the actual recipient animal. Such a technique will not provide suitable transplant organs to those patients whose cells or organs are deficient, i.e., perhaps for lack of gene expression, or due to expression of a mutant gene. Moreover, for a patient whose organ has literally shut down, it will not be possible to engineer a new organ from the patient's own cells. Thus, there are many deficiencies to be overcome in applying the concepts of cellular differentiation and development and tissue engineering to the treatment of transplant patients.
Summary of Invention The present invention addresses the uncertainties still to be overcome in the use of engineered cells and tissues for transplantation. The invention discloses methods of engineering cloned, immune compatible, developmentally differentiated cells into tissues for transplantation, and methods of using such tissues to treat a patient in need of a transplant. In particular, such tissues may be designed to express a therapeutic protein. Because the tissues and cells for transplantation are all generated from the same original donor cell through nuclear transfer, all the cells of the engineered tissue will express the heterologous gene of interest. The methods of the invention therefore additionally provide an invaluable alternative to tissue-targeted gene therapy.
The present invention also provides methods for determining whether particular genetically engineered cells will provide immune compatible organs for transplantation. For instance, the present invention discloses methods of evaluating cloned cells for mitochondria) compatibility, and in particular, transgenic, developmentally differentiated cells, for immune compatibility in an animal model.
Such evaluations will provide important information regarding the suitability of therapeutic tissues in transplantation, and will provide the foundation for controlling these parameters in order to provide immune compatible tissues.
Detailed Description The present invention is directed to methods of producing of immune compatible tissues using cloning technology. The cells and engineered tissues produced by the disclosed methods are also encompassed in the present invention, as are the stable grafts produced by transplantation of the engineered tissues. A
stable graft is defined as a graft that does not illicit an immune response or rejection when transplanted into a nuclear donor, or at least provides a substantial improvement in avoiding graft rejection over non-cloned control transplanted tissue.
Because cloned cells generated by nuclear transfer are not completely identical with the donor cell or animal, e.g., they typically lack the mitochondria) DNA
of the donor cell and gain the mitochondria) DNA of the recipient enucleated oocyte or other cell and typically are not produced in an in vivo environment that will perfectly mimic conditions present during embryogenesis, the question is raised as to whether such cells will be entirely immune-compatible when they are transplanted back into the donor animal.
For instance, it has been demonstrated that mitochondria) peptides in mice, e.g., the ND 1 peptide from the amino terminus of NADH dehydrogenase and the MiHA peptide encoded by the amino terminus of the COI gene, are presented at the cell surface by non-classical MHC class I molecules, e.g., H-2M3a, in combination with beta-2-microglobulin (Vyas et al., 1992, "Biochemical specificity of H-2M3a . .
.," J. Immunol. 149(11):3605-11; Morse et al., 1996, "The COI mitochondria) gene encodes a minor histocompatibility antigen presented by H2-M3," J. Immunol.
156(9): 3301-7). It has also been shown that allelic variation at a single residue in the ND 1 peptide renders cells displaying foreign alleles susceptible to lysis by specific cytotoxic T cells (Loveland et al. 1990. 60(6): 971-80). A similar system has been identified in rats, although the mitochondria) peptide which is responsible for histocompatibility in the rat is not the same as the allelic ND1 peptide from mice (Davies et al., 1991, "Generation of T cells with lytic specificity for atypical antigens.
I. A mitochondria) antigen in the rat," J. Exp. Med. 173: 823-32).
Thus, mitochondria) peptides displayed at the cell surface can serve as histocompatibiliy antigens, seeing as two separate systems have been identified in mice and rats, respectively. There is no reason to believe that similar systems would not be present in other mammals. Therefore, foreign mitochondria would be expected to result in the rejection of therapeutic tissue generated by nuclear transfer technology. Instead, using the methods of the present invention, the present inventors have surprisingly found in performing the methods of the present invention that nuclear transfer generated cells having allogeneic mitochondria are not rejected when transplanted into the nuclear donor.
Despite the fact that cloned tissues having allogeneic mitochondria were not rejected after transplant, the question of transplant compatibility becomes even more relevant when such cells are transfected with a transgene or undergo some other genetic manipulation in order to modify, supplement or bolster the function of the transplanted tissue. Accordingly, the present invention provides methods and animal models for testing the immune compatibility of cloned cells or tissues in an animal model, and for enhancing the immune compatibility of such cells or tissues as needed.
Generally, such methods comprise:
I S a. obtaining a cell from a donor animal;
b. transferring the nucleus from said cell into a recipient oocyte or other suitable recipient cell to generate an embryo and optionally introducing a therapeutic heterologous DNA;
c. isolating an embryonic disc, inner cell mass, and/or stem cell from said embryo;
d. injecting said disc and/or stem cell into said donor animal at the same time as control embryonic disc and/or stem cell; and e. examining the injection sites for teratoma formation, and signs of subsequent rejection.
For the purposes of the present invention, a teratoma is defined as a group of differentiated cells containing derivatives of mesoderm, endoderm, or ectoderm resulting from totipotent cells. A control embryonic disc, inner cell mass, or stem cell is one which was not generated using a donor cell from the test animal (allogeneic or xenogeneic nuclear DNA), and therefore, the teratoma thus generated from such disc or cell is expected to be rejected in the donor animal, or alternatively, may never develop at all. Teratomas generated using a nucleus from the donor animal (isogenic) and an allogeneic recipient oocyte or other suitable recipient cell would also be expected to be rejected when used in transplantation due to presentation of mitochondria) alleles as histocompatibility antigens. Thus, the fact that such therapeutic tissues do not lead to transplant rejection is truly surprising indeed.
Donor and control embryonic discs, inner cell mass, and/or stem cells are generally injected intramuscularly, introduced under the renal capsule, subcutaneously or into the paralumbar fascia. Where a teratoma is formed, it is removed and examined for the presence of germ layers, which may further be separated for the purpose of detecting or isolating specific cell types. While teratoma formation may give an initial indication of immune compatibility, specific cell types may be generated and re-introduced into the donor animal to further test immune compatibility, particularly where the transfected heterologous gene is expressed from a cell-type specific promoter. Given that the cloned tissues of the present invention having allogeneic mitochondria were not rejected, this system is ideal for testing the affect of a transgene on tissue compatibility whereby the cell from said donor animal is transfected with a heterologous gene prior to nuclear transfer.
Generally, the methods of the invention may be performed using any cell from the donor animal. Suitable cells include by way of example immune cells such as B
cells, T cells, dendritic cells, skin cells such as keratinocytes, epithelial cells, chondrocytes, cumulus cells, neural cells, cardiac cells, esophagial cells, primordial germ cells, cells of various organs including the liver, stomach, intestines, lung, kidneys, etc. In general, the most appropriate cells are easily propagatable in tissue culture and can be easily transfected. Preferably, cell types for transfecting heterologous DNA and performing nuclear transfer are fibroblasts.
The animal model may be any animal suitable for generating teratomas and studying immune compatibility. A preferred animal is an ungulate, and more preferred is a bovine. Alternatively, the animal may be a non-human primate, e.g., a baboon or cynomolgus monkey. Large animals are preferred because they may give rise to larger teratomas, thereby providing more cells for immunological evaluation and for transplantation. Suitable animals include by way of example pigs, dogs, horses, buffalo and goats.
Also included in the present invention are methods of testing the immune compatibility of cloned teratomas in cross-species animal models, e.g., where the nucleus of the donor species is inserted into a recipient oocyte or other suitable recipient cell of another species (xenogeneic). Cloned teratomas having the mitochondria from the recipient cell may then be tested for immune compatibility by injecting an embryonic disc, inner cell mass, and/or stem cell into the donor animal.
Particularly preferred are cross-species models involving closely related species, where the mitochondria) proteins of the recipient cell would be expected to function in combination with the donor nucleus.
For instance, according to a report in the New York Times on November 12, 1998 (Nicholas Wade, "Human Cells Revert to Embryo State, Scientists Assert"), although cow mitochondria would not be expected to work with a human nucleus, the mitochondria of chimpanzees and gorillas would be expected to be functional in human cells. In fact, as noted on the website www~lobalchan eg com, scientists have already made chimeric "geep" (combined sheep and goat), and "camas" (combined camels and lamas), suggesting that the cells and cellular organelles of closely related species would be functionally compatible (see also "Bush telegraph on chimeras,"
The Daily Telegraph, January 22, 1998, p. 27; "It's a geep: cross-breeding goats and sheep," Time, February 27, 1984, p. 71; "Meet the geep: part goat - part sheep,"
i n e, May 1984, 5: 6). According to Jakovcic et al. (1975, "Sequence homology between mitochondria) DNAs of different eukaryotes," Biochem. 14(10): 2043-50), evolutionary divergence of mtDNA sequences appears to have occurred at rates similar to that for unique sequence nuclear DNA.
Such cross-species models have particular relevance to the study of xenotransplantation, and would provide a convenient model for identifying the mitochondria) proteins that serve as histocompatibility antigens. If the mitochondria of the recipient cell prove to be functionally, but not immunologically, compatible using the teratoma model, it will be possible to identify mitochondria) antigens and peptides which are displayed on the cell surface but may not exhibit allelic variation within a single species. Such a model will facilitate recombinant DNA
methodology geared toward replacing the relevant mitochondria) antigens in the recipient cell with those from the nuclear transfer donor, in order to further enhance the immune compatibility of the cloned cells and tissues for transplantation therapy.
For instance, if cloned "cross-species" teratomas also show signs of rejection, steps may be taken in accordance with the invention to ensure that cloned cells and tissues are compatible with the nuclear donor, for instance, by selecting recipient cells which express compatible mitochondria) antigens, or by replacing the histocompatible mitochondria) epitopes. In fact, one group of researchers has reported complete replacement of endogenous mitochondria) DNA in one Drosophila species with the mitochondria) DNA of another (Niki et al. 1989. Complete replacement of mitochondria) DNA in Drosophila. Nature 341(6242): 551-2. Thus, it should be possible to engineer recipient cells that have a desired mitochondria) phenotype for any particular nuclear transfer donor, or even a mixture of mitochondria) phenotypes, i.e., isogenic and allogeneic, or isogeneic and cross-species.
Mitochondria) genes or DNA segments responsible for mitochondria) antigen histocompatibility, particularly in cross-species models, may be readily identified using the methods of the present invention. For instance, isogenic nuclei from a designated mammalian nuclear donor can be transferred into different allogeneic mitochondria) backgrounds of a closely related species, and such cells may be used to immunize the nuclear transfer donor in order to isolate and identify antibodies and lymphocytes specific for mitochondria) epitopes. By comparing the specificities of the panels of antibodies and lymphocytes achieved by immunizing the nuclear donor, it is possible to identify mitochondria) antigens and epitopes that result in immune recognition and possibly graft rejection in cross-species models.
Identification of such mitochondria) antigens and epitopes will allow replacement of the corresponding encoding DNA, such that transplant rejection of cross-species nuclear transfer generated cloned tissues may be avoided.
Thus, the present invention includes methods of identifying mitochondria) histocomptibility antigens using cross-species nuclear transfer, comprising:
obtaining cells from a donor mammal;
transfernng nuclei from said donor mammal into at least two recipient oocytes or other suitable recipient cells of a mammalian species other than said nuclear donor to generate embryos, wherein said at least two recipient cells are allogeneic with regard to mitochondria) DNA;
isolating embryonic discs and/or stem cells from said embryos;
injecting said discs and/or stem cells separately back into said donor mammal as to generate a specific panel of antibodies and/or lymphocytes; and comparing panels of antibodies and/or lymphocytes generated in response to said allogeneic mitochondria) backgrounds in order to identify mitochondria) antigens and/or epitopes that are recognized by the immune system of said donor mammal.
Antibodies and lymphocytes (both helper and cytotoxic T-cells and B-cells) specific for the mitochondria) antigens identified in such methods are also encompassed by the present invention, as are the mitochondria) peptides, antigens, and DNAs or DNA fragments encoding the same.
The ability to re-clone cloned mammals and generate a line of cloned mammals that are isogenic for both nuclear and mitochondria) DNA allows for concurrent injection of the cross-species cloned cells containing allogeneic mitochondria into separate mammals, thereby facilitating the retrieval of panels of antibodies and lymphocytes specific for different mitochondria) backgrounds.
Methods of recloning cloned mammals based on the observation that nuclear transfer can be used to rejuvenate senescent cells are disclosed in commonly assigned, copending Application Serial No. , filed concurrently herewith and incorporated by reference in its entirety. Of course, it is also possible to generate cloned mammals having isogenic mitochondria) DNA by performing nuclear transfer from a single donor using multiple oocytes or other suitable recipient cells from a single recipient mammal or cell line. Thus the methods of the present invention may also be performed wherein said discs and/or stem cells are injected into separate mammals which are isogenic to the nuclear donor with respect to both nuclear and mitochondria) DNA in order to isolate panels of antibodies and/or lymphocytes.
The present invention also encompasses methods of generating therapeutic cloned tissue for transplant which express a heterologous protein. The heterologous DNAs to be used in the methods of the present invention may encode a therapeutic protein to be expressed in a transplant recipient, but may also be a reporter gene for the purpose of monitoring gene expression in the teratoma. The reporter gene may be any which is convenient for monitoring gene expression, but is preferably selected from the group consisting of green flourescent protein (GFP), beta-galactosidase, luciferase, variants thereof, antibiotic resistance markers, or other markers.
Also, the use of tissue-specific promoters or tissue specific enhancers provides a means of selecting for expression of heterologous DNAs in desired tissue types.
Alternatively, the cells may be selected based on the expression characteristics of cell surface markers. For example, hematopoietic stem cells may be selected based on CD34 expression.
While the donor cell may also contain deletions and insertions into the genome that disrupt or modify the expression of native genes, preferably the donor cell is transfected with a heterologous gene that encodes a protein that is secreted and performs a therapeutic function in the intended transplant recipient, i.e., replaces a native gene which is mutated, or is not expressed. Where it is found that the expressed protein generates an immune response, the animal used in the animal model to test immune compatibility may then be used for the evaluation of the immune response and the isolation of antibodies or cytotoxic T cell clones.
The teratomas generated in animals used to test immune compatibility of cloned tissues will also be useful for the study of molecular signals that control cell differentiation and development. For instance, reporter gene constructs designed with putative developmental promoters, enhancers, repressors or other gene control sequences may be inserted into the donor nucleus prior to nuclear transfer, and the teratomas may then be monitored visually or by other means to see at which stage reporter gene expression is turned on.
As described above, the differentiated teratoma cells may be separated and used to individually test the immune compatibility of a particular cell or tissue. Once a particular cell type of interest is identified, it may be used to engineer a tissue using the methods described herein and known in the art. The animal models disclosed find particular use in testing new matrix materials in tissue engineering for immune compatibility. Preferred engineered tissues of the present invention are selected from the group consisting of smooth muscle, skeletal muscle, cardiac muscle, skin, kidney and nervous tissue.
Thus, the present invention also concerns methods of generating immune compatible tissues for transplantation, comprising:
obtaining a donor cell from an intended transplant recipient;
b. transferring the nucleus from said cell into a recipient oocyte or other suitable recipient cell to generate an embryo;
c. isolating an embryonic disc, inner cell mass, and/or stem cell from said embryo;
d. injecting said disc, inner cell mass, and/or stem cell into an immune compromised animal;
e. isolating the resulting teratoma;
f. isolating from the teratoma a cell of the type required for transplantation, and optionally expanding said cells in vitro using a growth factor; and g. engineering a tissue from said cells or combinations of cells.
It will also be possible as the signals for cell differentiation and development are identified to produce the desired cell types for tissue engineering and transplantation without prior teratoma formation, because the development of particular cell types will be directed in vitro. Alternatively, at least with mammals other than humans, it is currently possible to acquire cloned tissues directly from growing embryos or fetuses rather than generate a teratoma. Humans may be next, however, at least for harvesting cell types that develop during the first two weeks of embryogenesis, if a recent recommendation by a high ranking British science and ethics commission results in legislation (see Weiss, "British panel urges allowing human embryo cloning," The Washington Post, page A26, August 17, 2000).
Tissue engineering may be effected, e.g., using three-dimensional scaffolds or biodegradable polymers such as are used in the construction of dissolvable sutures.
Such methods have been well reported in the patent and non-patent literature by companies such as Tissue Engineering, Inc. and Organogenesis. Examples of patents and references in the area of tissue engineering include U.S. Patent 5,948,429, 5,709,934, 5,983,888, 5,891,558, 5,709,934, 5,851,290, 5,800,537, 5,882,929, 5,800,537, 5,891,558, 5,709,934, 5,891,617, 5,518,878, 5,766,937, 5,733,337, 5,718,012, 5,712,163, and 5,256,418, all of which are incorporated by reference in their entirety. Also, reference is made to numerous patents and literature references by Robert Langer and John Vacanti, who are both prolific in the area of tissue regeneration research. As discussed in many of there patents, it may be desirable to include biologicals that facilitate blood tissue development, i.e., growth factors and other compounds that promote angiogensis.
In particular, the immune-compatible tissues and cells generated are useful in methods of providing a patient in need of a transplant with an immune-compatible transplant. Such a method further comprises, in addition to the above steps, transplanting said engineered tissue into a patient. The fact that the present inventors have surprisingly found that cloned cells containing isogenic nuclear DNA and allogeneic mitochondria) DNA do not induce transplant rejection has particular relevance for transplants which replace native cells suffering from mitochondria) damage, for instance as in amythrophic lateral sclerosis (ALS), or Leber's hereditary optic neuropathy (LHON). In such cases, cloned tissue having isogenic nuclear DNA
and allogeneic mitochondria) DNA that does not induce an immune reaction is the most ideal tissue for transplantation in that such tissue not only provides the closest histocompatibility match, but it also effectuates mitochondria) gene therapy in that tissue containing damaged mitochondria is replaced.
For instance, Dhaliwal and colleagues recently demonstrated that brain tissue from patients with ALS had a thirty-fold higher incidence of the "common mutation,"
which is a 4977 base-pair mutation deletion observed in various tissues of patients with mitochondria) and other disorders ("Mitochondria) DNA deletion mutation levels are elevated in ALS brains," Mol. Neurosci. 11(113): 2507-9). In fact, an accumulation of mtDNA49~7 has been observed in the brains, hearts and muscles of healthy older individuals suggesting a contribution to the aging process in these tissues (Soong and Amheim, 1995, Methods Neurosci. 26: 105-28). Thus, cloned tissues having allogeneic "young" mitochondria) DNA might provide an advantage over the patient's own cells by virtue of the absence of age-related mitochondria) mutations.
Mitochondria) DNA is believed to be more susceptible to age-related mutations than is genomic DNA because of the relative lack of DNA repair mechanisms and histones (Dhaliwal et al. 2000). However, there are also hereditary mitochondria) mutations transmitted maternally that manifest themselves in particular tissues, that would benefit by the cloning and tissue engineering techniques in the present application.
For instance, Leber's hereditary optic neuropathy (LHON) is a rare disorder of the optic nerve that causes legal blindness in most patients that it affects.
It is caused by a mutation in the mitochondria) DNA that is passed maternally, however, the disease typically manifests itself later in life (sudden loss of vision in the first eye typically occurs at the age of 10-50) (Zickermann et al., 1998, "Analysis of the pathogenic human mitochondria) mutation ND1/3460, and mutations of strictly conserved residues in its vicinity . . .," Biochem. 37(34): 11792-6).
Researchers at the Molecular Ophthalmology Laboratory at the University of Iowa have developed an improved method for detecting the mutation, which is used to diagnose LHON.
The cloning, tissue engineering, and transplantation techniques of the present invention will be especially valuable for replacing diseased tissue linked to mitochondria) mutations in that the cloned tissues will typically possess isogenic nuclear DNA, but allogeneic mitochondria) DNA. Therefore, for instance, engineered nervous tissue for transplantation into LHON patients will effectuate gene therapy of the mitochondria) DNA while at the same time, replace the diseased optic nerve tissue.
As described above, said donor cell may be genetically altered prior to nuclear transfer by the transfection of at least one heterologous gene, or the disruption or replacement of at least one native gene. Such a genomic modification is particularly useful where the transplant recipient's own genome fails to express a required protein, or expresses a mutated protein such that the original tissue or organ failed to function properly. Alternatively or additionally, if prior tests of immune compatibility suggest some rejection is anticipated, e.g., due to allogeneic or xenogeneic differences in mitochondria) DNA, the donor cell may be transfected with genes expressing proteins that deter or decrease immune rejection prior to nuclear transfer.
The methods of the present invention are particularly useful for repairing and replacing tissues damage by autoimmune diseases due to the aberrant expression of self peptides. For instance, primary biliary cirrhosis (PBC) is a chronic autoimmune liver disease characterized by progressive inflammatory obliteration of the intrahepatic bile ducts ultimately leading to cirrhosis (Melegh et al., 2000, "Autoantibodies against subunits of pyruvate dehydrogenase and citrate synthase in a case of paediatric biliary cirrhosis," Gut 2: 753-6). The disease is characterized by decreased tolerance to self mitochondria) proteins, and is associated with high titers of anti-mitochondria) antibodies, which may be detected using techniques known in the art (Leung et al., 1991, "Use of designer recombinant mitochondria) antigens in the diagnosis of primary biliary cirrhosis," Hepatol. 15(3): 367-72). Liver transplantation has become the treatment of choice with patients with advanced disease (Sebagh et al., 1998, "Histological features predictive of recurrence of primary biliary cirrhosis after liver transplant," Transplantation 65(10): 1328-33).
The anti-mitochondria) antibodies in PBC typically recognize a restricted epitope on the E2 subunit of the pyruvate dehydrogenase complex (PDC), which is a nuclear encoded protein which is normally transported into the mitochondria and loosely associated with the inner membrane. Although the PDC protein is normally shielded from the immune system, patients having PBC have been shown to express PDC-E2 on the surface of biliary epithelial cells (Joplin et al., 1992, "Distribution of dihydrolipoamide acetyltransferase (E2) in the liver and portal lymph nodes of patients with primary biliary cirrhosis: an immunohistochemical study,"
Hepatology 14: 442-7). Thus, one theory as to how PBC is initiated is that a nuclear genetic alteration affects the transport of PDC-E2 to the mitochondria, i.e., such as mutations in the leader sequence that direct E2 to the outer membrane (Bjorkland and Totterman, 1994, "Is primary biliary cirrhosis an autoimmune disease?" Scand.
J.
Gastroenterol. 29 Suppl. 204: 32-9).
Thus, in the case of PBC, the nuclear transfer-generated cells can be corrected for the nuclear defects that lead to the autoimmune disease prior to generation of the liver cells and tissues for transplantation, i.e., by replacing the mutated leader sequence. As a result, the cloned cells and tissues used for transplantation into a PBC
patient would not only provide the closest immune compatible tissue to avoid rejection, but also effectuate gene therapy which repairs a nuclear gene linked to the autoimmune disease itself. The methods of the present invention are equally as valuable for the transplantation and gene therapy of any diseased tissue where the nuclear mutations associated with the disease process have been identified, e.g., for the treatment of burns, blood disorders, cancer, chronic pain, diabetes, dwarfism, epilepsy, heart disease such as myocardial infarction, hemophilic, infertility, kidney disease, liver disease, osteoarthritis, osteoporosis, stroke, affective disorders, Alzheimer's disease, enzymatic defects, Huntington's disease, hypocholesterolemine, hypoparathyroidase, immunodeficiencies, Lou Gehrig's disease, macular degeneration, multiple sclerosis, muscular dystrophy, Parkinson's disease, rheumatoid arthritis, and spinal cord injuries.
In this regard, it is pertinent to note that the present inventors have also discovered that the cloning procedures of the present invention enables the rejuvenation of senescent cells, thereby foregoing any concerns regarding the genetic age of cloned tissues. The disclosure of U.S. application Serial No. 09/ , which is co-owned with the present application, reports the inventors' surprising observations relating to the rejuvenation of primary cells using nuclear transfer, and is herein incorporated in its entirety. The finding that the cloning process rejuvenates older cells is particularly relevant for designing therapeutic tissues expressing more than one heterologous gene, or having more than one gene knocked out, because such tissues can be generated by cloning and re-cloning primary cells of the same genetic background.
It is also possible to effectuate changes to the mitochondria) DNA of the recipient cell using techniques known in the art (see Wheeler et al. 1997.
Modification of the mouse mitochondria) genome by insertion of an exogenous gene. Gene 198(1-2): 203-9; Yamaoka et al. 2000. Complete repopulation of mouse mitochondria) DNA-less cells with rat mitochondria) DNA . . . Genetics 155(1): 301-7). This may be helpful for generating immune compatible cells and tissues for transplantation, particularly in the case where mitochondria) antigens are displayed by the cloned cells, and generate an immune response when the cloned cells are transplanted back into the nuclear donor. Alternatively, if pretesting shows that transplant rejection due to mitochondria) DNA differences is anticipated, particularly in the case of xenogeneic mitochondria, the suitable recipient cell may be particularly selected based on mitochondria) compatibility.
Although any animal may benefit from the cells and tissues generated by the disclosed methods, a preferred transplant recipient is a human. When the intended transplant recipient is a human, teratomas may be formed following nuclear transfer, i.e., of a fibroblast nucleus, from said human into any human recipient oocyte, because it is the genome of the donor (intended transplant recipient) that reprograms the cell for development. Teratomas generated from human nuclear donors and recipients may be formed in and isolated from an immune compromised animal, such as a skid or nude mouse.
As described above, the teratomas generated may be removed and examined for the formation of germ layers, and such germ layers may be further separated or differentiated into distinct cell types. Distinct cell types may then be used to engineer tissues for transplantation. Preferably, said tissues are selected from the group consisting of smooth muscle, skeletal muscle, cardiac muscle, skin, kidney and nervous tissue. Also encompassed are the tissues and cells generated by the disclosed methods.
The concept of human "therapeutic cloning" is to transfer the nucleus from one of the patient's cells, i.e., a fibroblast cell, into an enucleated recipient oocyte or other suitable recipient cell. After reprogramming, the donated somatic nucleus regains its totipotency and is able to initiate a round of embryonic development.
Pluripotent stem cells derived from the resulting embryo carry the nuclear genome of the patient, and are then induced to differentiate into replacement cells, such as cardiomyocytes to replace damaged heart tissue, insulin-producing n-cells for patients with diabetes, chrondrocytes for osteoarthritis, or dopaminergic neurons to treat Parkinson's disease.
The methods of the invention should eliminate or at least substantially alleviate the immune responses associated with transplantation of these various tissues, and therefore abrogate the requirement for immunosuppressive drugs, such as cyclosporine, imoran, FK-506, glucocorticoids, and variants thereof, which carry the risk of a wide variety of serious complications, including cancer, infection, renal failure and osteoporosis. However, at least in some instances, it may still be advisable to utilize anti-rejection agents at least initially. As discussed above, the transplanted cells may not be immunologically identical to the transplant recipient's cells, even though the nucleus of one of the recipient's cells served as the donor. This could be caused by mitochondria) DNA differences particularly in the case of xenogeneic mitochondria, or antigenic differences that may result from transfected heterologous DNA or because of the artificial environment used to affect nuclear transfer.
In particular, such an environment does not mimic identically the cellular environment that exits during embryonic development.
For example, it is known that cells cultured for prolonged periods may be antigenically different as a result of culturing (a phenomenon known as "antigenic drift"). Therefore, it may still be desirable to tolerize the cells or tissues prior to transplantation, e.g. by treatment with soluble CD40, CD40-ligand antagonists, low temperature culture, use of antibodies that mask donor antigens, or by expression of UV light (e.g., islets).
Although not limiting, the scope and spirit of the invention are illustrated by reference to the following discussion and examples.
EXAMPLE I
This experiment was designed to test the immune compatibility of a nuclear transfer-generated cells in a pre-clinical large animal model: cattle (Bos taurus).
Three adult Holstein steers approximately 8-10 months old (weighing approximately 500-1000 Ibs) were purchased from Thomas Morns, Inc., Maryland, and shipped to the South Deerfield Farm at the University of Massachusetts, Amherst.
1 S To obtain fibroblasts for nuclear transfer, skin biopsies were obtained from each of the animals by ear notch. A plasmid which expresses a reporter gene encoding enhanced green fluorescent protein (eGFP) was transfected into the cells, and transfected cells were selected with neomycin. Purified cells, analyzed by PCR
and/
or FISH, were used for nuclear transfer as described previously in Nature (1998) Biotechnol. 16: 642-646, herein incorporated by reference.
Isolated embryos having at least one cell, or embryonic discs/ inner cell mass or stem cells generated from bovine blastocysts/ stem cells are then injected into the paralumbar fascia of the donor steers (two sites with experimental (same animal) stem cells, two sites with experimental (same animal) embryonic discs, two sites with inner cell mass, and four sites with control (different animal) stem cells, per animal). After two months, the muscle is examined for teratoma formation. Any tumors identified are removed for histological analysis.
The procedure is performed on the standing animal using 20 mg Xylazine/ 8 mg Butorphanol Tatrate administered IV in the tail vein. The paralumbar fascia area is clipped and surgically prepared, using 100 ml of 2% Lidocaine as a local anesthetic administered as a paralumbar block. The animals should be given antibiotics for three days post-surgically as a precautionary measure (Cefilofur Hcl 50 mg/cc @
lcc/100 pounds). Immediately following surgery a single injection intramuscularly or under the kidney capsule of Flunixin Meglumine @ lcc/100 pounds may be given to control pain and swelling at the surgical site. If teratoma formation does not occur at the paralumbar fascia, other sites may be analyzed, i.e,. subcutaneously.
It is expected that "same animal" stem cells will survive in the recipient (donor of nucleus) animal in contrast to "different animal" stem cells, or survive at least better or longer depending on the cytotoxic T cell response or other immune reaction to foreign mitochondria) peptides. Furthermore, it is expected that cells from all three germ layers, i.e., ectoderm, mesoderm, and endoderm, will be observed in "same animal" teratomas.
This example was designed to test teratoma formation in an immune-compromised animal model. This example is relevant to the methods whereby cloned, nuclear transfer-generated cells from a patient in need of a transplant may be grown in a SCID mouse or other immune-compromised animal in order to generate differentiated cells for isolation and design of engineered tissues for transplant.
ES cells transfected with GFP were derived from two adult Holstein steers (two different ES cell lines were derived from each animal). ICMs were derived from 12-day-old blastocysts.
Cell preparation and injection procedure:
Cells were cut into pieces (sections of no more than about 100 cells each) and loaded into a 1 ml syringe, no more than 200 microliters each, and preferably microliters.
ICMS were mechanically isolated and loaded into a 1-ml syringe 100 to 150 microliters.
Cells were kept at room temperature in HECM-Hepes.
Twenty-two-gauge needles were used for injection procedures. Cells were injected into the skeletal muscle of the hind leg of SCID mice.
Mou Treatment Amount I Observatio se # ns 1 ICM day 14 from cow 6 100 #
2 ICM day 14 from cow 9 3 ICMs #22 were found left inside the syringe 3 Monkey cross-species 90 -(into bovine) 4-8 cell embryos 4 ES 22.B One plate (30 -mm) ES 22.B Three plates -6 ES 22.C One plate 7 ES 22.C Three plates -8 ES 25.E One plate -9 ES 25.E Three plates -ES 25.F One plate -right 10 ES 25.F Three plates -left Bovine stem cells and ICMs that were injected into the skeletal muscle of the SCID mice were retrieved after 7-8 weeks (although it is possible to let the cells go longer, or remove them sooner). A small nodular lesion was identified in two of the mice which received ES cell injections (mice #s 7 and 9).
Gross Examination:
A 2X2 mm sized milky white nodule was retrieved from the right hind leg near the sciatic nerve of mouse #7. This corresponds with the injection of three plates of ES 22.C. A 1X 1 mm sized milky white nodule was identified within the muscle 10 tissue of mouse # 9 which corresponds with the injection of the three plates of ES
25.F.
Histologic Analysis:
Mouse #7: Histologic sections of the teratoma were analyzed with hematoxylin and eosin (H&E), safranin-O and immunocytochemistry using cytokeratin (AE1/AE3) and alpha smooth muscle actin antibodies.
H&E: The injected cells formed a round tissue mass within the skeletal muscle tissue. The teratoma consisted of four different sized compartments with cellular debris in the center. Tissue formation was noted on the wall of each compartment (data not shown). Epithelial (round nuclei) and stromal cells (spindle-shaped nuclei) were observed in the teratoma tissue (data not shown). There was no evidence of cartilage, bone or adipose tissue.
Safranin-O: Negative staining was obtained, which indicates the absence of cartilage tissue formation.
Immunocytochemistry with AE1/AE3 antibodies: The teratoma section showed positively stained epithelial cells (data not shown).
Immunocytochemistry with alpha smooth actin antibodies: Small islands of positively stained muscle tissue was observed within the teratoma (data not shown). The retrieved tissue demonstrated epithelial, smooth muscle and stromal tissue components. Cartilage, bone and adipose tissues were not identified in the teratoma.
Mouse # 9: Histologic analysis on the retrieved nodule demonstrated a skeletal muscle mass. Microscopic examination showed that no other tissues formed.
To realize the full potential of therapeutic cloning, it will be important to reconstitute more complex tissues and organs in vitro. Although cloning would eliminate or greatly alleviate the most critical problem--immune compatibility--there is still the task of putting the cells together to create or recreate functional structures.
For example, myocardial infarction is one of the most common diagnoses occurring in hospitalized patients in western countries. While injection of individual or small groups of cardiomyocytes could aid in the treatment of some localized infarcts, this approach is unlikely to be of value in patients with more extended ischemic injury, where the risk of scar formation, cardiac rupture and other complications is much greater. Tissue engineering offers the possibility of organizing the cells into three-dimensional myocardial "patches" which could be used to repair the damaged portions of the heart. For myocardium and other relatively simple tissues, such as skin and blood vessel substitutes, this may involve seeding cells onto masses or sheets of polymeric scaffold. Creating more complex, vital organs, such as the kidney, liver, or even an entire heart will require assembling different cell types and materials in greater combinatorial complexity.
To engineer tissues for use in the animal model, bovine inner cell mass/embryonic discs/stem cells may be generated as described above, and injected into the rear leg muscles of nude or SCID mice. Seven to eight weeks after injection, the resulting teratomas are removed and various cell types are isolated and grown in culture. A number of tissues may be generated from the cloned cells, including smooth and/or skeletal muscle, sheets or "patches" of cardiomyocytes, elastic cartilage, skin, (including the placement of hair follicles), and kidney, including miniature kidneys that excrete urine. These tissues/ organ constructs are then transplanted back into the original adult animal from which the donor cell biopsy was obtained.
The following data demonstrates that tissues isogenic for nuclear DNA and allogeneic for mitochondria) DNA form stable transplantation grafts that do not illicit an immune response in the nuclear transfer host. This supports the utility of such cloned cells and tissues for many medical applications, which is quite surprising given the cytotoxic T cell response to mitochondria) antigens observed in different species of mice in response to mitochondria) histocompatibility antigens.
CELL CULTURE AND SEEDING
Cells from bovine kidney, heart, skeletal muscle, cartilage and skin were harvested from cloned and allogenic (control) 40 day old fetuses, and expanded separately in vitro.
Kidney:
The kidney tissue was cut into small pieces (1 mm') using sharp tenotomy scissors. The kidney tissue fragments were digested using collagenase dispase (1 mg/ml) at 37° C for 30 minutes. The recovered cells were washed with phosphate buffered saline and plated in culture dishes. The cells were grown in medium consisting of DMEM, HEPES 3.1 g/1, Pen/Strep (5 m1/500 ml), L-glutamine 146 mg/L and FBS 10% (Sigma, St. Louis, MO).
Muscle:
Cardiac and skeletal muscle cells were processed by the tissue explant technique using Dulbecco's Modified Eagle's Medium (DMEM; HyClone Laboratories, Inc., Logan, Utah) supplemented with 10% fetal calf serum. The cells were incubated in a humidified atmosphere chamber containing 5% COZ and maintained at 37°C. Both muscle cell types were expanded separately until desired cell numbers were obtained. The cells were trypsinized, collected, washed and counted for seeding.
Polymers:
Unwoven sheets of polyglycolic acid polymers ( 1 x 2 cm) were used as cell delivery vehicles. The polymer meshes were composed of fibers of 15 ~m in diameter and an interfiber distance between 0 - 200 um with 95% porosity. The scaffold was designed to degrade via hydrolysis in 8-12 weeks. The polymers were sterilized in ethylene oxide and placed under sterile conditions until cell delivery.
IMPLANTATION
Athymic Mice:
To determine whether cells obtained from fetal bovine tissue would form tissue in vivo, cardiomyocytes, skeletal muscle cells and chondrocytes seeded on polymer scaffolds were implanted in the dorsal subcutaneous space of athymic mice.
The animals were sacrificed at 1 week, 1 month and 3 months after implantation for analyses (n=4).
Steer:
Each cell type was seeded separately onto polyglycolic acid polymers (1 x 2 cm) at a concentration of 50 x 106 cells/cm3 (n=4 per cell types). The cell-polymer scaffolds were implanted into the flank subcutaneous space of the same steer from which the cells were cloned. The cells obtained from the control (nuclear allogeneic) fetuses were implanted on the contralateral flank of the steer. All implants were retrieved after 6 weeks for analysis.
ANALYSES
Implantation in Athymic Mice:
Five micron sections of formalin fixed paraffin embedded tissue were cut and stained with hematoxylin and eosin (H&E). Immunocytochemical analyses were performed using specific antibodies in order to identify the cell type of the retrieved tissues. Histochemical analyses using aldehyde fuschin-alcian blue, and immunocytochemical studies using monoclonal anti-collagen II (Chemicon, St.
Louis, MO) were used to identify the engineered cartilage structures. Monoclonal sarcomeric tropomyosin (Sigma, St. Louis, MO) and troponin I (Chemicon, Temecula, CA) antibodies were used to detect skeletal and cardiac muscle fibers, respectively. Immunolabeling was performed using he avidin-biotin detection system. Sections were counterstained with methyl green.
Implantation in the Steer:
Immunocytochemical and histological analyses:
Five micron sections of formalin fixed paraffin embedded tissue were cut and stained with hematoxylin and eosin (H&E). Immunocytochemical analyses were performed using specific antibodies in order to identify the cell type of the retrieved tissues. Histochemical analysis using Periodic Acid Schiff (Sigma, St.
Louis, MO), and immunocytochemical studies using polyclonal anti-alkaline phosphatase and anti-osteopontin (Chemicon, Temecula, CA) were used to identify renal cells. Monoclonal sarcomeric tropomyosin (Sigma, St. Louis ,MO) and troponin I (Chemicon, Temecula, CA) antibodies were used to detect skeletal and cardiac muscle fibers, respectively. Aldehyde fuschin-alcian blue and monoclonal anti-collagen II (Chemicon, St. Louis, MO) were used to stain cartilage tissue implants. Anti-cytokeratins 5/6, AE1/AE3 were employed in order to identify keratinocytes. Bronchial ciliary antibodies were used in order to detect respiratory epithelium. Anti-CD6 antibodies were used in order to identify immune T and B
cells. Immunolabeling was performed using the avidin-biotin detection system.
Sections were counterstained with methyl green.
RESULTS
The cells grew to confluence, were implanted in the animals with the polymer scaffolds, and retrieved without complications. At retrieval, the implants maintained their initial size without any evidence of fibrosis.
Implants retrieved from the steer:
Histochemical and Immunocytochemical Analyses:
Histological examination demonstrated extensive vascularization throughout the implants and the presence of multinucleated giant cells were observed surrounding the polymer fibers. However, higher number of inflammatory cells were present throughout the control allogeneic scaffolds. Histomorphomeric analysis of the explanted tissue (i.e., kidney, skeletal, heart, chondrocytes and keratinocytes) indicated that there was a statistically significant (p<0.05; student's t-test) increase in lymphocytic infiltration of the control implants/constructs (non-cloned) versus the cloned tissue types (data not shown). This data suggests that the control grafts were undergoing early graft rejection.
Engineered Kidney Tissue:
Histologically, glomeruli-like structures were observed in the retrieved scaffolds (data not shown). Histochemical analyses using periodic acid schiff identified renal tubular cells (data not shown). Immunocytochemical studies with alkaline phosphatases antibodies confirmed the presence of proximal tubular cells.
Studies using osteopontin antibodies were negative in the bovine tissue system.
Engineered Muscle Tissue:
Retrieved cardiac and skeletal muscle cell implants showed spatially oriented muscle fibers in each instance (data not shown). Immunocytochemical analysis using tropomyosin antibodies identified skeletal muscle fibers within the construct (data not shown). Anti-troponin I stained cardiac muscle fibers positively (data not shown).
To prove that the mtDNA of the cloned tissues was from the recipient oocyte, the mtDNA of the nuclear donor and that of the cloned embryo were sequenced.
Sequence data confirmed that the mtDNAs were indeed different, particularly in the d-loop region where there were four different corresponding nucleotides in the cloned tissues in comparison with the nuclear donor.
The above results suggest that it is possible to generate cloned tissues for transplantation by nuclear transfer into an allogeneic background, and that differentiated cells and tissues isolated or constructed from cloned teratomas or cultures of embryonic cells can be transplanted back into the donor animal without significant signs of rejection. To further confirm that nuclear transfer technology has the potential to eliminate the immune responses associated with the transplantation of cells and organs despite mitochondria) mismatch, the inventors will next perform transplants between full grown clones having different mitochondria) backgrounds.
For these experiments, two groups of animals were assembled to test reciprocal skin grafts: (1) four cloned cows (animals CL53-8, CL53-9, CL53-10, and CL53-11) at Trans Ova and (2) five cloned goats at LSU. To perform the test, reciprocal skin grafts (approximately 2-3 cm diameter) are exchanged between the two groups of animals. Self grafts will serve as positive controls, whereas grafts from genetically unrelated animals will serve as negative controls. The grafts are monitored for signs of immune rejection, and will be removed if and when they become necrotic and the sites patched. If rejection is observed, second-set grafts would then be transplanted in order to confirm the results, which should be rejected in an accelerated fashion.
All of the cloned cows and all of the cloned goats carry the same nuclear genome. However, since mtDNA is transmitted by maternal inheritance, we predict the animals are in fact genetic chimeras with different oocyte-derived mitochondria (this has already been documented in a number of cloned animals). Experiments are underway to obtain the sequence of the mtDNAs from all involved individuals, so that polymorphisms which "segregate" in these panels of animals may be readily correlated with the survival/rejection of skin grafts. If there is a correlation, in vitro assays will be performed to identify target peptides, and the associated mtDNAs which encode the peptides will be isolated.
The experiments aimed at determining mitochondria) DNA polymorphisms will also reveal information about chimerism levels in mtDNA in general. For instance, once the sequences of the mtDNAs are known, a region of maximal polymorphism will be selected, most likely the D-loop, and this segment will be amplified and cloned. A range of clones may then be sequenced to the determine extent of variation in this region. With the mtDNA sequences from a sufficient number of nuclear clones that are allogeneic for mitochondria, an accurate estimate of the levels of chimerism may be determined. Blood samples will also be collected at intervals to carry out various immunological assays. For histocompatibility, standard MLCs and CMLs will be run within the panels and with allogeneic cells.
DISCUSSION
As shown by the data provided above, the present invention demonstrates that it is possible to obtain cloned differentiated cells and tissues for the purpose of tissue engineering and transplantation. The present invention also demonstrates that stable grafts can be achieved with nuclear transfer-generated cloned cells having allogeneic mitochondria, despite the fact that transplantation rejection would be expected due to foreign mitochondria) peptides. In view of the Mta system in mice and similar systems identified in rats, it is surprising that the bovine tissues engineered using the present methods were not rejected when they were transplanted back into the nuclear donor.
There could be several reasons why transplant rejection was not observed with the cloned tissues of the present invention. Without being bound by any particular theory, one hypothesis is that the particular MHC molecules in rodents that present the Mtf , MiHA and other mitochondria) antigens have evolved out of higher mammals. Indeed, H-2M3a, the mouse class I molecule that presents the Mtf and MiHA peptides, is encoded by the M3 gene at the telomeric end of the H-2 complex on mouse chromosome 17 (Fischer Lindahl et al., "Maternally transmitted antigen of mice: a model transplantation antigen," Annu. Rev. Immunol. 1991;9:351-72).
Although many genes in this area of the chromosome are conserved between mouse and human, for instance, the MHC class I genes in this region appear to have diverged and evolved independently between species (Jones et al., 1999, "MHC class I
and non-class I gene organization in the proximal H2-M region of the mouse,"
Immuno eg netics 49(3): 183-95). In fact, the H2-M region is rich in LI
repeats, which some have hypothesized is associated with evolutionary flexibility (Yoshino et al., 1997, "Genomic evolution of the distal MHC class I region on mouse chromosome 17," H r i a 127(1-2): 141-8).
Alternatively, perhaps additional mechanisms evolved in higher mammals which regulate the immune reaction to mitochondria) antigens in the context of MHC, particularly seeing as many aging but otherwise healthy tissues in humans have been shown to contain mitochondria) age-related mutations (Soong and Amheim, 1995).
The ongoing experiments described in Example 4 will be especially useful for identifying the polymorphims that exist in a given population of mtDNAs, and may serve as a useful model system for identifying the changes that occur in mtDNAs over time that may lead to the aberrant display and recognition of mitochondria) antigens.
In any case, despite what was known and understood about rodent mitochondria) histocompatibility prior to the present invention, the results achieved with the therapeutic cloned bovine tissues described herein would predictably translate to other ungulates and higher mammals. Thus, the present invention confirms the therapeutic utility of nuclear transfer-generated cloned tissues in the context of transplantation. Further, by providing a model for testing the immune compatibility of allogeneic and xenogeneic mitochondria) proteins in an isogenic nuclear background, the present invention paves the way for deciphering the immune regulatory systems that exist in and between mammals, which contribute to mitochondria) stability and the separate evolution of species.
Particularly preferred are cross-species models involving closely related species, where the mitochondria) proteins of the recipient cell would be expected to function in combination with the donor nucleus.
For instance, according to a report in the New York Times on November 12, 1998 (Nicholas Wade, "Human Cells Revert to Embryo State, Scientists Assert"), although cow mitochondria would not be expected to work with a human nucleus, the mitochondria of chimpanzees and gorillas would be expected to be functional in human cells. In fact, as noted on the website www~lobalchan eg com, scientists have already made chimeric "geep" (combined sheep and goat), and "camas" (combined camels and lamas), suggesting that the cells and cellular organelles of closely related species would be functionally compatible (see also "Bush telegraph on chimeras,"
The Daily Telegraph, January 22, 1998, p. 27; "It's a geep: cross-breeding goats and sheep," Time, February 27, 1984, p. 71; "Meet the geep: part goat - part sheep,"
i n e, May 1984, 5: 6). According to Jakovcic et al. (1975, "Sequence homology between mitochondria) DNAs of different eukaryotes," Biochem. 14(10): 2043-50), evolutionary divergence of mtDNA sequences appears to have occurred at rates similar to that for unique sequence nuclear DNA.
Such cross-species models have particular relevance to the study of xenotransplantation, and would provide a convenient model for identifying the mitochondria) proteins that serve as histocompatibility antigens. If the mitochondria of the recipient cell prove to be functionally, but not immunologically, compatible using the teratoma model, it will be possible to identify mitochondria) antigens and peptides which are displayed on the cell surface but may not exhibit allelic variation within a single species. Such a model will facilitate recombinant DNA
methodology geared toward replacing the relevant mitochondria) antigens in the recipient cell with those from the nuclear transfer donor, in order to further enhance the immune compatibility of the cloned cells and tissues for transplantation therapy.
For instance, if cloned "cross-species" teratomas also show signs of rejection, steps may be taken in accordance with the invention to ensure that cloned cells and tissues are compatible with the nuclear donor, for instance, by selecting recipient cells which express compatible mitochondria) antigens, or by replacing the histocompatible mitochondria) epitopes. In fact, one group of researchers has reported complete replacement of endogenous mitochondria) DNA in one Drosophila species with the mitochondria) DNA of another (Niki et al. 1989. Complete replacement of mitochondria) DNA in Drosophila. Nature 341(6242): 551-2. Thus, it should be possible to engineer recipient cells that have a desired mitochondria) phenotype for any particular nuclear transfer donor, or even a mixture of mitochondria) phenotypes, i.e., isogenic and allogeneic, or isogeneic and cross-species.
Mitochondria) genes or DNA segments responsible for mitochondria) antigen histocompatibility, particularly in cross-species models, may be readily identified using the methods of the present invention. For instance, isogenic nuclei from a designated mammalian nuclear donor can be transferred into different allogeneic mitochondria) backgrounds of a closely related species, and such cells may be used to immunize the nuclear transfer donor in order to isolate and identify antibodies and lymphocytes specific for mitochondria) epitopes. By comparing the specificities of the panels of antibodies and lymphocytes achieved by immunizing the nuclear donor, it is possible to identify mitochondria) antigens and epitopes that result in immune recognition and possibly graft rejection in cross-species models.
Identification of such mitochondria) antigens and epitopes will allow replacement of the corresponding encoding DNA, such that transplant rejection of cross-species nuclear transfer generated cloned tissues may be avoided.
Thus, the present invention includes methods of identifying mitochondria) histocomptibility antigens using cross-species nuclear transfer, comprising:
obtaining cells from a donor mammal;
transfernng nuclei from said donor mammal into at least two recipient oocytes or other suitable recipient cells of a mammalian species other than said nuclear donor to generate embryos, wherein said at least two recipient cells are allogeneic with regard to mitochondria) DNA;
isolating embryonic discs and/or stem cells from said embryos;
injecting said discs and/or stem cells separately back into said donor mammal as to generate a specific panel of antibodies and/or lymphocytes; and comparing panels of antibodies and/or lymphocytes generated in response to said allogeneic mitochondria) backgrounds in order to identify mitochondria) antigens and/or epitopes that are recognized by the immune system of said donor mammal.
Antibodies and lymphocytes (both helper and cytotoxic T-cells and B-cells) specific for the mitochondria) antigens identified in such methods are also encompassed by the present invention, as are the mitochondria) peptides, antigens, and DNAs or DNA fragments encoding the same.
The ability to re-clone cloned mammals and generate a line of cloned mammals that are isogenic for both nuclear and mitochondria) DNA allows for concurrent injection of the cross-species cloned cells containing allogeneic mitochondria into separate mammals, thereby facilitating the retrieval of panels of antibodies and lymphocytes specific for different mitochondria) backgrounds.
Methods of recloning cloned mammals based on the observation that nuclear transfer can be used to rejuvenate senescent cells are disclosed in commonly assigned, copending Application Serial No. , filed concurrently herewith and incorporated by reference in its entirety. Of course, it is also possible to generate cloned mammals having isogenic mitochondria) DNA by performing nuclear transfer from a single donor using multiple oocytes or other suitable recipient cells from a single recipient mammal or cell line. Thus the methods of the present invention may also be performed wherein said discs and/or stem cells are injected into separate mammals which are isogenic to the nuclear donor with respect to both nuclear and mitochondria) DNA in order to isolate panels of antibodies and/or lymphocytes.
The present invention also encompasses methods of generating therapeutic cloned tissue for transplant which express a heterologous protein. The heterologous DNAs to be used in the methods of the present invention may encode a therapeutic protein to be expressed in a transplant recipient, but may also be a reporter gene for the purpose of monitoring gene expression in the teratoma. The reporter gene may be any which is convenient for monitoring gene expression, but is preferably selected from the group consisting of green flourescent protein (GFP), beta-galactosidase, luciferase, variants thereof, antibiotic resistance markers, or other markers.
Also, the use of tissue-specific promoters or tissue specific enhancers provides a means of selecting for expression of heterologous DNAs in desired tissue types.
Alternatively, the cells may be selected based on the expression characteristics of cell surface markers. For example, hematopoietic stem cells may be selected based on CD34 expression.
While the donor cell may also contain deletions and insertions into the genome that disrupt or modify the expression of native genes, preferably the donor cell is transfected with a heterologous gene that encodes a protein that is secreted and performs a therapeutic function in the intended transplant recipient, i.e., replaces a native gene which is mutated, or is not expressed. Where it is found that the expressed protein generates an immune response, the animal used in the animal model to test immune compatibility may then be used for the evaluation of the immune response and the isolation of antibodies or cytotoxic T cell clones.
The teratomas generated in animals used to test immune compatibility of cloned tissues will also be useful for the study of molecular signals that control cell differentiation and development. For instance, reporter gene constructs designed with putative developmental promoters, enhancers, repressors or other gene control sequences may be inserted into the donor nucleus prior to nuclear transfer, and the teratomas may then be monitored visually or by other means to see at which stage reporter gene expression is turned on.
As described above, the differentiated teratoma cells may be separated and used to individually test the immune compatibility of a particular cell or tissue. Once a particular cell type of interest is identified, it may be used to engineer a tissue using the methods described herein and known in the art. The animal models disclosed find particular use in testing new matrix materials in tissue engineering for immune compatibility. Preferred engineered tissues of the present invention are selected from the group consisting of smooth muscle, skeletal muscle, cardiac muscle, skin, kidney and nervous tissue.
Thus, the present invention also concerns methods of generating immune compatible tissues for transplantation, comprising:
obtaining a donor cell from an intended transplant recipient;
b. transferring the nucleus from said cell into a recipient oocyte or other suitable recipient cell to generate an embryo;
c. isolating an embryonic disc, inner cell mass, and/or stem cell from said embryo;
d. injecting said disc, inner cell mass, and/or stem cell into an immune compromised animal;
e. isolating the resulting teratoma;
f. isolating from the teratoma a cell of the type required for transplantation, and optionally expanding said cells in vitro using a growth factor; and g. engineering a tissue from said cells or combinations of cells.
It will also be possible as the signals for cell differentiation and development are identified to produce the desired cell types for tissue engineering and transplantation without prior teratoma formation, because the development of particular cell types will be directed in vitro. Alternatively, at least with mammals other than humans, it is currently possible to acquire cloned tissues directly from growing embryos or fetuses rather than generate a teratoma. Humans may be next, however, at least for harvesting cell types that develop during the first two weeks of embryogenesis, if a recent recommendation by a high ranking British science and ethics commission results in legislation (see Weiss, "British panel urges allowing human embryo cloning," The Washington Post, page A26, August 17, 2000).
Tissue engineering may be effected, e.g., using three-dimensional scaffolds or biodegradable polymers such as are used in the construction of dissolvable sutures.
Such methods have been well reported in the patent and non-patent literature by companies such as Tissue Engineering, Inc. and Organogenesis. Examples of patents and references in the area of tissue engineering include U.S. Patent 5,948,429, 5,709,934, 5,983,888, 5,891,558, 5,709,934, 5,851,290, 5,800,537, 5,882,929, 5,800,537, 5,891,558, 5,709,934, 5,891,617, 5,518,878, 5,766,937, 5,733,337, 5,718,012, 5,712,163, and 5,256,418, all of which are incorporated by reference in their entirety. Also, reference is made to numerous patents and literature references by Robert Langer and John Vacanti, who are both prolific in the area of tissue regeneration research. As discussed in many of there patents, it may be desirable to include biologicals that facilitate blood tissue development, i.e., growth factors and other compounds that promote angiogensis.
In particular, the immune-compatible tissues and cells generated are useful in methods of providing a patient in need of a transplant with an immune-compatible transplant. Such a method further comprises, in addition to the above steps, transplanting said engineered tissue into a patient. The fact that the present inventors have surprisingly found that cloned cells containing isogenic nuclear DNA and allogeneic mitochondria) DNA do not induce transplant rejection has particular relevance for transplants which replace native cells suffering from mitochondria) damage, for instance as in amythrophic lateral sclerosis (ALS), or Leber's hereditary optic neuropathy (LHON). In such cases, cloned tissue having isogenic nuclear DNA
and allogeneic mitochondria) DNA that does not induce an immune reaction is the most ideal tissue for transplantation in that such tissue not only provides the closest histocompatibility match, but it also effectuates mitochondria) gene therapy in that tissue containing damaged mitochondria is replaced.
For instance, Dhaliwal and colleagues recently demonstrated that brain tissue from patients with ALS had a thirty-fold higher incidence of the "common mutation,"
which is a 4977 base-pair mutation deletion observed in various tissues of patients with mitochondria) and other disorders ("Mitochondria) DNA deletion mutation levels are elevated in ALS brains," Mol. Neurosci. 11(113): 2507-9). In fact, an accumulation of mtDNA49~7 has been observed in the brains, hearts and muscles of healthy older individuals suggesting a contribution to the aging process in these tissues (Soong and Amheim, 1995, Methods Neurosci. 26: 105-28). Thus, cloned tissues having allogeneic "young" mitochondria) DNA might provide an advantage over the patient's own cells by virtue of the absence of age-related mitochondria) mutations.
Mitochondria) DNA is believed to be more susceptible to age-related mutations than is genomic DNA because of the relative lack of DNA repair mechanisms and histones (Dhaliwal et al. 2000). However, there are also hereditary mitochondria) mutations transmitted maternally that manifest themselves in particular tissues, that would benefit by the cloning and tissue engineering techniques in the present application.
For instance, Leber's hereditary optic neuropathy (LHON) is a rare disorder of the optic nerve that causes legal blindness in most patients that it affects.
It is caused by a mutation in the mitochondria) DNA that is passed maternally, however, the disease typically manifests itself later in life (sudden loss of vision in the first eye typically occurs at the age of 10-50) (Zickermann et al., 1998, "Analysis of the pathogenic human mitochondria) mutation ND1/3460, and mutations of strictly conserved residues in its vicinity . . .," Biochem. 37(34): 11792-6).
Researchers at the Molecular Ophthalmology Laboratory at the University of Iowa have developed an improved method for detecting the mutation, which is used to diagnose LHON.
The cloning, tissue engineering, and transplantation techniques of the present invention will be especially valuable for replacing diseased tissue linked to mitochondria) mutations in that the cloned tissues will typically possess isogenic nuclear DNA, but allogeneic mitochondria) DNA. Therefore, for instance, engineered nervous tissue for transplantation into LHON patients will effectuate gene therapy of the mitochondria) DNA while at the same time, replace the diseased optic nerve tissue.
As described above, said donor cell may be genetically altered prior to nuclear transfer by the transfection of at least one heterologous gene, or the disruption or replacement of at least one native gene. Such a genomic modification is particularly useful where the transplant recipient's own genome fails to express a required protein, or expresses a mutated protein such that the original tissue or organ failed to function properly. Alternatively or additionally, if prior tests of immune compatibility suggest some rejection is anticipated, e.g., due to allogeneic or xenogeneic differences in mitochondria) DNA, the donor cell may be transfected with genes expressing proteins that deter or decrease immune rejection prior to nuclear transfer.
The methods of the present invention are particularly useful for repairing and replacing tissues damage by autoimmune diseases due to the aberrant expression of self peptides. For instance, primary biliary cirrhosis (PBC) is a chronic autoimmune liver disease characterized by progressive inflammatory obliteration of the intrahepatic bile ducts ultimately leading to cirrhosis (Melegh et al., 2000, "Autoantibodies against subunits of pyruvate dehydrogenase and citrate synthase in a case of paediatric biliary cirrhosis," Gut 2: 753-6). The disease is characterized by decreased tolerance to self mitochondria) proteins, and is associated with high titers of anti-mitochondria) antibodies, which may be detected using techniques known in the art (Leung et al., 1991, "Use of designer recombinant mitochondria) antigens in the diagnosis of primary biliary cirrhosis," Hepatol. 15(3): 367-72). Liver transplantation has become the treatment of choice with patients with advanced disease (Sebagh et al., 1998, "Histological features predictive of recurrence of primary biliary cirrhosis after liver transplant," Transplantation 65(10): 1328-33).
The anti-mitochondria) antibodies in PBC typically recognize a restricted epitope on the E2 subunit of the pyruvate dehydrogenase complex (PDC), which is a nuclear encoded protein which is normally transported into the mitochondria and loosely associated with the inner membrane. Although the PDC protein is normally shielded from the immune system, patients having PBC have been shown to express PDC-E2 on the surface of biliary epithelial cells (Joplin et al., 1992, "Distribution of dihydrolipoamide acetyltransferase (E2) in the liver and portal lymph nodes of patients with primary biliary cirrhosis: an immunohistochemical study,"
Hepatology 14: 442-7). Thus, one theory as to how PBC is initiated is that a nuclear genetic alteration affects the transport of PDC-E2 to the mitochondria, i.e., such as mutations in the leader sequence that direct E2 to the outer membrane (Bjorkland and Totterman, 1994, "Is primary biliary cirrhosis an autoimmune disease?" Scand.
J.
Gastroenterol. 29 Suppl. 204: 32-9).
Thus, in the case of PBC, the nuclear transfer-generated cells can be corrected for the nuclear defects that lead to the autoimmune disease prior to generation of the liver cells and tissues for transplantation, i.e., by replacing the mutated leader sequence. As a result, the cloned cells and tissues used for transplantation into a PBC
patient would not only provide the closest immune compatible tissue to avoid rejection, but also effectuate gene therapy which repairs a nuclear gene linked to the autoimmune disease itself. The methods of the present invention are equally as valuable for the transplantation and gene therapy of any diseased tissue where the nuclear mutations associated with the disease process have been identified, e.g., for the treatment of burns, blood disorders, cancer, chronic pain, diabetes, dwarfism, epilepsy, heart disease such as myocardial infarction, hemophilic, infertility, kidney disease, liver disease, osteoarthritis, osteoporosis, stroke, affective disorders, Alzheimer's disease, enzymatic defects, Huntington's disease, hypocholesterolemine, hypoparathyroidase, immunodeficiencies, Lou Gehrig's disease, macular degeneration, multiple sclerosis, muscular dystrophy, Parkinson's disease, rheumatoid arthritis, and spinal cord injuries.
In this regard, it is pertinent to note that the present inventors have also discovered that the cloning procedures of the present invention enables the rejuvenation of senescent cells, thereby foregoing any concerns regarding the genetic age of cloned tissues. The disclosure of U.S. application Serial No. 09/ , which is co-owned with the present application, reports the inventors' surprising observations relating to the rejuvenation of primary cells using nuclear transfer, and is herein incorporated in its entirety. The finding that the cloning process rejuvenates older cells is particularly relevant for designing therapeutic tissues expressing more than one heterologous gene, or having more than one gene knocked out, because such tissues can be generated by cloning and re-cloning primary cells of the same genetic background.
It is also possible to effectuate changes to the mitochondria) DNA of the recipient cell using techniques known in the art (see Wheeler et al. 1997.
Modification of the mouse mitochondria) genome by insertion of an exogenous gene. Gene 198(1-2): 203-9; Yamaoka et al. 2000. Complete repopulation of mouse mitochondria) DNA-less cells with rat mitochondria) DNA . . . Genetics 155(1): 301-7). This may be helpful for generating immune compatible cells and tissues for transplantation, particularly in the case where mitochondria) antigens are displayed by the cloned cells, and generate an immune response when the cloned cells are transplanted back into the nuclear donor. Alternatively, if pretesting shows that transplant rejection due to mitochondria) DNA differences is anticipated, particularly in the case of xenogeneic mitochondria, the suitable recipient cell may be particularly selected based on mitochondria) compatibility.
Although any animal may benefit from the cells and tissues generated by the disclosed methods, a preferred transplant recipient is a human. When the intended transplant recipient is a human, teratomas may be formed following nuclear transfer, i.e., of a fibroblast nucleus, from said human into any human recipient oocyte, because it is the genome of the donor (intended transplant recipient) that reprograms the cell for development. Teratomas generated from human nuclear donors and recipients may be formed in and isolated from an immune compromised animal, such as a skid or nude mouse.
As described above, the teratomas generated may be removed and examined for the formation of germ layers, and such germ layers may be further separated or differentiated into distinct cell types. Distinct cell types may then be used to engineer tissues for transplantation. Preferably, said tissues are selected from the group consisting of smooth muscle, skeletal muscle, cardiac muscle, skin, kidney and nervous tissue. Also encompassed are the tissues and cells generated by the disclosed methods.
The concept of human "therapeutic cloning" is to transfer the nucleus from one of the patient's cells, i.e., a fibroblast cell, into an enucleated recipient oocyte or other suitable recipient cell. After reprogramming, the donated somatic nucleus regains its totipotency and is able to initiate a round of embryonic development.
Pluripotent stem cells derived from the resulting embryo carry the nuclear genome of the patient, and are then induced to differentiate into replacement cells, such as cardiomyocytes to replace damaged heart tissue, insulin-producing n-cells for patients with diabetes, chrondrocytes for osteoarthritis, or dopaminergic neurons to treat Parkinson's disease.
The methods of the invention should eliminate or at least substantially alleviate the immune responses associated with transplantation of these various tissues, and therefore abrogate the requirement for immunosuppressive drugs, such as cyclosporine, imoran, FK-506, glucocorticoids, and variants thereof, which carry the risk of a wide variety of serious complications, including cancer, infection, renal failure and osteoporosis. However, at least in some instances, it may still be advisable to utilize anti-rejection agents at least initially. As discussed above, the transplanted cells may not be immunologically identical to the transplant recipient's cells, even though the nucleus of one of the recipient's cells served as the donor. This could be caused by mitochondria) DNA differences particularly in the case of xenogeneic mitochondria, or antigenic differences that may result from transfected heterologous DNA or because of the artificial environment used to affect nuclear transfer.
In particular, such an environment does not mimic identically the cellular environment that exits during embryonic development.
For example, it is known that cells cultured for prolonged periods may be antigenically different as a result of culturing (a phenomenon known as "antigenic drift"). Therefore, it may still be desirable to tolerize the cells or tissues prior to transplantation, e.g. by treatment with soluble CD40, CD40-ligand antagonists, low temperature culture, use of antibodies that mask donor antigens, or by expression of UV light (e.g., islets).
Although not limiting, the scope and spirit of the invention are illustrated by reference to the following discussion and examples.
EXAMPLE I
This experiment was designed to test the immune compatibility of a nuclear transfer-generated cells in a pre-clinical large animal model: cattle (Bos taurus).
Three adult Holstein steers approximately 8-10 months old (weighing approximately 500-1000 Ibs) were purchased from Thomas Morns, Inc., Maryland, and shipped to the South Deerfield Farm at the University of Massachusetts, Amherst.
1 S To obtain fibroblasts for nuclear transfer, skin biopsies were obtained from each of the animals by ear notch. A plasmid which expresses a reporter gene encoding enhanced green fluorescent protein (eGFP) was transfected into the cells, and transfected cells were selected with neomycin. Purified cells, analyzed by PCR
and/
or FISH, were used for nuclear transfer as described previously in Nature (1998) Biotechnol. 16: 642-646, herein incorporated by reference.
Isolated embryos having at least one cell, or embryonic discs/ inner cell mass or stem cells generated from bovine blastocysts/ stem cells are then injected into the paralumbar fascia of the donor steers (two sites with experimental (same animal) stem cells, two sites with experimental (same animal) embryonic discs, two sites with inner cell mass, and four sites with control (different animal) stem cells, per animal). After two months, the muscle is examined for teratoma formation. Any tumors identified are removed for histological analysis.
The procedure is performed on the standing animal using 20 mg Xylazine/ 8 mg Butorphanol Tatrate administered IV in the tail vein. The paralumbar fascia area is clipped and surgically prepared, using 100 ml of 2% Lidocaine as a local anesthetic administered as a paralumbar block. The animals should be given antibiotics for three days post-surgically as a precautionary measure (Cefilofur Hcl 50 mg/cc @
lcc/100 pounds). Immediately following surgery a single injection intramuscularly or under the kidney capsule of Flunixin Meglumine @ lcc/100 pounds may be given to control pain and swelling at the surgical site. If teratoma formation does not occur at the paralumbar fascia, other sites may be analyzed, i.e,. subcutaneously.
It is expected that "same animal" stem cells will survive in the recipient (donor of nucleus) animal in contrast to "different animal" stem cells, or survive at least better or longer depending on the cytotoxic T cell response or other immune reaction to foreign mitochondria) peptides. Furthermore, it is expected that cells from all three germ layers, i.e., ectoderm, mesoderm, and endoderm, will be observed in "same animal" teratomas.
This example was designed to test teratoma formation in an immune-compromised animal model. This example is relevant to the methods whereby cloned, nuclear transfer-generated cells from a patient in need of a transplant may be grown in a SCID mouse or other immune-compromised animal in order to generate differentiated cells for isolation and design of engineered tissues for transplant.
ES cells transfected with GFP were derived from two adult Holstein steers (two different ES cell lines were derived from each animal). ICMs were derived from 12-day-old blastocysts.
Cell preparation and injection procedure:
Cells were cut into pieces (sections of no more than about 100 cells each) and loaded into a 1 ml syringe, no more than 200 microliters each, and preferably microliters.
ICMS were mechanically isolated and loaded into a 1-ml syringe 100 to 150 microliters.
Cells were kept at room temperature in HECM-Hepes.
Twenty-two-gauge needles were used for injection procedures. Cells were injected into the skeletal muscle of the hind leg of SCID mice.
Mou Treatment Amount I Observatio se # ns 1 ICM day 14 from cow 6 100 #
2 ICM day 14 from cow 9 3 ICMs #22 were found left inside the syringe 3 Monkey cross-species 90 -(into bovine) 4-8 cell embryos 4 ES 22.B One plate (30 -mm) ES 22.B Three plates -6 ES 22.C One plate 7 ES 22.C Three plates -8 ES 25.E One plate -9 ES 25.E Three plates -ES 25.F One plate -right 10 ES 25.F Three plates -left Bovine stem cells and ICMs that were injected into the skeletal muscle of the SCID mice were retrieved after 7-8 weeks (although it is possible to let the cells go longer, or remove them sooner). A small nodular lesion was identified in two of the mice which received ES cell injections (mice #s 7 and 9).
Gross Examination:
A 2X2 mm sized milky white nodule was retrieved from the right hind leg near the sciatic nerve of mouse #7. This corresponds with the injection of three plates of ES 22.C. A 1X 1 mm sized milky white nodule was identified within the muscle 10 tissue of mouse # 9 which corresponds with the injection of the three plates of ES
25.F.
Histologic Analysis:
Mouse #7: Histologic sections of the teratoma were analyzed with hematoxylin and eosin (H&E), safranin-O and immunocytochemistry using cytokeratin (AE1/AE3) and alpha smooth muscle actin antibodies.
H&E: The injected cells formed a round tissue mass within the skeletal muscle tissue. The teratoma consisted of four different sized compartments with cellular debris in the center. Tissue formation was noted on the wall of each compartment (data not shown). Epithelial (round nuclei) and stromal cells (spindle-shaped nuclei) were observed in the teratoma tissue (data not shown). There was no evidence of cartilage, bone or adipose tissue.
Safranin-O: Negative staining was obtained, which indicates the absence of cartilage tissue formation.
Immunocytochemistry with AE1/AE3 antibodies: The teratoma section showed positively stained epithelial cells (data not shown).
Immunocytochemistry with alpha smooth actin antibodies: Small islands of positively stained muscle tissue was observed within the teratoma (data not shown). The retrieved tissue demonstrated epithelial, smooth muscle and stromal tissue components. Cartilage, bone and adipose tissues were not identified in the teratoma.
Mouse # 9: Histologic analysis on the retrieved nodule demonstrated a skeletal muscle mass. Microscopic examination showed that no other tissues formed.
To realize the full potential of therapeutic cloning, it will be important to reconstitute more complex tissues and organs in vitro. Although cloning would eliminate or greatly alleviate the most critical problem--immune compatibility--there is still the task of putting the cells together to create or recreate functional structures.
For example, myocardial infarction is one of the most common diagnoses occurring in hospitalized patients in western countries. While injection of individual or small groups of cardiomyocytes could aid in the treatment of some localized infarcts, this approach is unlikely to be of value in patients with more extended ischemic injury, where the risk of scar formation, cardiac rupture and other complications is much greater. Tissue engineering offers the possibility of organizing the cells into three-dimensional myocardial "patches" which could be used to repair the damaged portions of the heart. For myocardium and other relatively simple tissues, such as skin and blood vessel substitutes, this may involve seeding cells onto masses or sheets of polymeric scaffold. Creating more complex, vital organs, such as the kidney, liver, or even an entire heart will require assembling different cell types and materials in greater combinatorial complexity.
To engineer tissues for use in the animal model, bovine inner cell mass/embryonic discs/stem cells may be generated as described above, and injected into the rear leg muscles of nude or SCID mice. Seven to eight weeks after injection, the resulting teratomas are removed and various cell types are isolated and grown in culture. A number of tissues may be generated from the cloned cells, including smooth and/or skeletal muscle, sheets or "patches" of cardiomyocytes, elastic cartilage, skin, (including the placement of hair follicles), and kidney, including miniature kidneys that excrete urine. These tissues/ organ constructs are then transplanted back into the original adult animal from which the donor cell biopsy was obtained.
The following data demonstrates that tissues isogenic for nuclear DNA and allogeneic for mitochondria) DNA form stable transplantation grafts that do not illicit an immune response in the nuclear transfer host. This supports the utility of such cloned cells and tissues for many medical applications, which is quite surprising given the cytotoxic T cell response to mitochondria) antigens observed in different species of mice in response to mitochondria) histocompatibility antigens.
CELL CULTURE AND SEEDING
Cells from bovine kidney, heart, skeletal muscle, cartilage and skin were harvested from cloned and allogenic (control) 40 day old fetuses, and expanded separately in vitro.
Kidney:
The kidney tissue was cut into small pieces (1 mm') using sharp tenotomy scissors. The kidney tissue fragments were digested using collagenase dispase (1 mg/ml) at 37° C for 30 minutes. The recovered cells were washed with phosphate buffered saline and plated in culture dishes. The cells were grown in medium consisting of DMEM, HEPES 3.1 g/1, Pen/Strep (5 m1/500 ml), L-glutamine 146 mg/L and FBS 10% (Sigma, St. Louis, MO).
Muscle:
Cardiac and skeletal muscle cells were processed by the tissue explant technique using Dulbecco's Modified Eagle's Medium (DMEM; HyClone Laboratories, Inc., Logan, Utah) supplemented with 10% fetal calf serum. The cells were incubated in a humidified atmosphere chamber containing 5% COZ and maintained at 37°C. Both muscle cell types were expanded separately until desired cell numbers were obtained. The cells were trypsinized, collected, washed and counted for seeding.
Polymers:
Unwoven sheets of polyglycolic acid polymers ( 1 x 2 cm) were used as cell delivery vehicles. The polymer meshes were composed of fibers of 15 ~m in diameter and an interfiber distance between 0 - 200 um with 95% porosity. The scaffold was designed to degrade via hydrolysis in 8-12 weeks. The polymers were sterilized in ethylene oxide and placed under sterile conditions until cell delivery.
IMPLANTATION
Athymic Mice:
To determine whether cells obtained from fetal bovine tissue would form tissue in vivo, cardiomyocytes, skeletal muscle cells and chondrocytes seeded on polymer scaffolds were implanted in the dorsal subcutaneous space of athymic mice.
The animals were sacrificed at 1 week, 1 month and 3 months after implantation for analyses (n=4).
Steer:
Each cell type was seeded separately onto polyglycolic acid polymers (1 x 2 cm) at a concentration of 50 x 106 cells/cm3 (n=4 per cell types). The cell-polymer scaffolds were implanted into the flank subcutaneous space of the same steer from which the cells were cloned. The cells obtained from the control (nuclear allogeneic) fetuses were implanted on the contralateral flank of the steer. All implants were retrieved after 6 weeks for analysis.
ANALYSES
Implantation in Athymic Mice:
Five micron sections of formalin fixed paraffin embedded tissue were cut and stained with hematoxylin and eosin (H&E). Immunocytochemical analyses were performed using specific antibodies in order to identify the cell type of the retrieved tissues. Histochemical analyses using aldehyde fuschin-alcian blue, and immunocytochemical studies using monoclonal anti-collagen II (Chemicon, St.
Louis, MO) were used to identify the engineered cartilage structures. Monoclonal sarcomeric tropomyosin (Sigma, St. Louis, MO) and troponin I (Chemicon, Temecula, CA) antibodies were used to detect skeletal and cardiac muscle fibers, respectively. Immunolabeling was performed using he avidin-biotin detection system. Sections were counterstained with methyl green.
Implantation in the Steer:
Immunocytochemical and histological analyses:
Five micron sections of formalin fixed paraffin embedded tissue were cut and stained with hematoxylin and eosin (H&E). Immunocytochemical analyses were performed using specific antibodies in order to identify the cell type of the retrieved tissues. Histochemical analysis using Periodic Acid Schiff (Sigma, St.
Louis, MO), and immunocytochemical studies using polyclonal anti-alkaline phosphatase and anti-osteopontin (Chemicon, Temecula, CA) were used to identify renal cells. Monoclonal sarcomeric tropomyosin (Sigma, St. Louis ,MO) and troponin I (Chemicon, Temecula, CA) antibodies were used to detect skeletal and cardiac muscle fibers, respectively. Aldehyde fuschin-alcian blue and monoclonal anti-collagen II (Chemicon, St. Louis, MO) were used to stain cartilage tissue implants. Anti-cytokeratins 5/6, AE1/AE3 were employed in order to identify keratinocytes. Bronchial ciliary antibodies were used in order to detect respiratory epithelium. Anti-CD6 antibodies were used in order to identify immune T and B
cells. Immunolabeling was performed using the avidin-biotin detection system.
Sections were counterstained with methyl green.
RESULTS
The cells grew to confluence, were implanted in the animals with the polymer scaffolds, and retrieved without complications. At retrieval, the implants maintained their initial size without any evidence of fibrosis.
Implants retrieved from the steer:
Histochemical and Immunocytochemical Analyses:
Histological examination demonstrated extensive vascularization throughout the implants and the presence of multinucleated giant cells were observed surrounding the polymer fibers. However, higher number of inflammatory cells were present throughout the control allogeneic scaffolds. Histomorphomeric analysis of the explanted tissue (i.e., kidney, skeletal, heart, chondrocytes and keratinocytes) indicated that there was a statistically significant (p<0.05; student's t-test) increase in lymphocytic infiltration of the control implants/constructs (non-cloned) versus the cloned tissue types (data not shown). This data suggests that the control grafts were undergoing early graft rejection.
Engineered Kidney Tissue:
Histologically, glomeruli-like structures were observed in the retrieved scaffolds (data not shown). Histochemical analyses using periodic acid schiff identified renal tubular cells (data not shown). Immunocytochemical studies with alkaline phosphatases antibodies confirmed the presence of proximal tubular cells.
Studies using osteopontin antibodies were negative in the bovine tissue system.
Engineered Muscle Tissue:
Retrieved cardiac and skeletal muscle cell implants showed spatially oriented muscle fibers in each instance (data not shown). Immunocytochemical analysis using tropomyosin antibodies identified skeletal muscle fibers within the construct (data not shown). Anti-troponin I stained cardiac muscle fibers positively (data not shown).
To prove that the mtDNA of the cloned tissues was from the recipient oocyte, the mtDNA of the nuclear donor and that of the cloned embryo were sequenced.
Sequence data confirmed that the mtDNAs were indeed different, particularly in the d-loop region where there were four different corresponding nucleotides in the cloned tissues in comparison with the nuclear donor.
The above results suggest that it is possible to generate cloned tissues for transplantation by nuclear transfer into an allogeneic background, and that differentiated cells and tissues isolated or constructed from cloned teratomas or cultures of embryonic cells can be transplanted back into the donor animal without significant signs of rejection. To further confirm that nuclear transfer technology has the potential to eliminate the immune responses associated with the transplantation of cells and organs despite mitochondria) mismatch, the inventors will next perform transplants between full grown clones having different mitochondria) backgrounds.
For these experiments, two groups of animals were assembled to test reciprocal skin grafts: (1) four cloned cows (animals CL53-8, CL53-9, CL53-10, and CL53-11) at Trans Ova and (2) five cloned goats at LSU. To perform the test, reciprocal skin grafts (approximately 2-3 cm diameter) are exchanged between the two groups of animals. Self grafts will serve as positive controls, whereas grafts from genetically unrelated animals will serve as negative controls. The grafts are monitored for signs of immune rejection, and will be removed if and when they become necrotic and the sites patched. If rejection is observed, second-set grafts would then be transplanted in order to confirm the results, which should be rejected in an accelerated fashion.
All of the cloned cows and all of the cloned goats carry the same nuclear genome. However, since mtDNA is transmitted by maternal inheritance, we predict the animals are in fact genetic chimeras with different oocyte-derived mitochondria (this has already been documented in a number of cloned animals). Experiments are underway to obtain the sequence of the mtDNAs from all involved individuals, so that polymorphisms which "segregate" in these panels of animals may be readily correlated with the survival/rejection of skin grafts. If there is a correlation, in vitro assays will be performed to identify target peptides, and the associated mtDNAs which encode the peptides will be isolated.
The experiments aimed at determining mitochondria) DNA polymorphisms will also reveal information about chimerism levels in mtDNA in general. For instance, once the sequences of the mtDNAs are known, a region of maximal polymorphism will be selected, most likely the D-loop, and this segment will be amplified and cloned. A range of clones may then be sequenced to the determine extent of variation in this region. With the mtDNA sequences from a sufficient number of nuclear clones that are allogeneic for mitochondria, an accurate estimate of the levels of chimerism may be determined. Blood samples will also be collected at intervals to carry out various immunological assays. For histocompatibility, standard MLCs and CMLs will be run within the panels and with allogeneic cells.
DISCUSSION
As shown by the data provided above, the present invention demonstrates that it is possible to obtain cloned differentiated cells and tissues for the purpose of tissue engineering and transplantation. The present invention also demonstrates that stable grafts can be achieved with nuclear transfer-generated cloned cells having allogeneic mitochondria, despite the fact that transplantation rejection would be expected due to foreign mitochondria) peptides. In view of the Mta system in mice and similar systems identified in rats, it is surprising that the bovine tissues engineered using the present methods were not rejected when they were transplanted back into the nuclear donor.
There could be several reasons why transplant rejection was not observed with the cloned tissues of the present invention. Without being bound by any particular theory, one hypothesis is that the particular MHC molecules in rodents that present the Mtf , MiHA and other mitochondria) antigens have evolved out of higher mammals. Indeed, H-2M3a, the mouse class I molecule that presents the Mtf and MiHA peptides, is encoded by the M3 gene at the telomeric end of the H-2 complex on mouse chromosome 17 (Fischer Lindahl et al., "Maternally transmitted antigen of mice: a model transplantation antigen," Annu. Rev. Immunol. 1991;9:351-72).
Although many genes in this area of the chromosome are conserved between mouse and human, for instance, the MHC class I genes in this region appear to have diverged and evolved independently between species (Jones et al., 1999, "MHC class I
and non-class I gene organization in the proximal H2-M region of the mouse,"
Immuno eg netics 49(3): 183-95). In fact, the H2-M region is rich in LI
repeats, which some have hypothesized is associated with evolutionary flexibility (Yoshino et al., 1997, "Genomic evolution of the distal MHC class I region on mouse chromosome 17," H r i a 127(1-2): 141-8).
Alternatively, perhaps additional mechanisms evolved in higher mammals which regulate the immune reaction to mitochondria) antigens in the context of MHC, particularly seeing as many aging but otherwise healthy tissues in humans have been shown to contain mitochondria) age-related mutations (Soong and Amheim, 1995).
The ongoing experiments described in Example 4 will be especially useful for identifying the polymorphims that exist in a given population of mtDNAs, and may serve as a useful model system for identifying the changes that occur in mtDNAs over time that may lead to the aberrant display and recognition of mitochondria) antigens.
In any case, despite what was known and understood about rodent mitochondria) histocompatibility prior to the present invention, the results achieved with the therapeutic cloned bovine tissues described herein would predictably translate to other ungulates and higher mammals. Thus, the present invention confirms the therapeutic utility of nuclear transfer-generated cloned tissues in the context of transplantation. Further, by providing a model for testing the immune compatibility of allogeneic and xenogeneic mitochondria) proteins in an isogenic nuclear background, the present invention paves the way for deciphering the immune regulatory systems that exist in and between mammals, which contribute to mitochondria) stability and the separate evolution of species.
Claims (55)
1. A method of testing the immune compatibility of cloned cells or tissues in an animal model, comprising:
a. obtaining a cell from a donor animal;
b. transferring the nucleus from said cell into a recipient oocyte or other suitable recipient cell to generate an embryo;
c. isolating an embryo having at least one cell, an embryonic disc and/or stem cell from said embryo;
d. injecting said embryo, disc and/or stem cell into said donor animal at the same time as control embryonic disc and/or stem cell; and e. examining the injection sites for teratoma formation.
a. obtaining a cell from a donor animal;
b. transferring the nucleus from said cell into a recipient oocyte or other suitable recipient cell to generate an embryo;
c. isolating an embryo having at least one cell, an embryonic disc and/or stem cell from said embryo;
d. injecting said embryo, disc and/or stem cell into said donor animal at the same time as control embryonic disc and/or stem cell; and e. examining the injection sites for teratoma formation.
2. The method of Claim 1, wherein said cell from said donor animal is transfected with a heterologous gene prior to nuclear transfer.
3. The method of Claim 1, wherein said donor and control embryonic discs and/or stem cells are injected subcutaneously or into the paralumbar fascia.
4. The method of Claim 1, wherein said teratoma, if formed, is removed and examined for the presence of germ layers.
5. The method of Claim 4, wherein the germ layers, if formed, are separated for the purpose of detecting or isolating specific cell types.
6. The method of Claim 1, wherein the cell obtained from said donor animal is a fibroblast.
7. The method of Claim 2, wherein said heterologous gene is a reporter gene selected from the group consisting of green flourescent protein (GFP), beta-galactosidase, and luciferase.
8. The method of Claim 2, wherein said heterologous gene encodes a protein that is secreted.
9. The method of Claim 8, wherein said protein generates an immune response.
10. The method of Claim 8, wherein said protein is a therapeutic protein.
11. The method of Claim 5, wherein the germ layer cells are further used in assays to evaluate potential developmental signals that control cell differentiation.
12. The method of Claim 5, wherein at least one type of cell found in the germ layers is used to engineer a tissue.
13. The method of Claim 12, wherein said engineered tissue is transplanted back into said donor animal to test immune compatibility.
14. The method of Claim 12, wherein said engineered tissue is selected from the group consisting of smooth muscle, skeletal muscle, cardiac muscle, skin, kidney and nervous tissue.
15. A method of generating immune compatible tissues for transplantation, comprising:
a. obtaining a donor cell from an intended transplant recipient;
b. transferring the nucleus from said cell into a recipient oocyte or other suitable recipient cell to generate an embryo or fetus;
c. isolating from the embryo or fetus a cell of the type required for transplantation; and d. engineering a tissue from said cells.
a. obtaining a donor cell from an intended transplant recipient;
b. transferring the nucleus from said cell into a recipient oocyte or other suitable recipient cell to generate an embryo or fetus;
c. isolating from the embryo or fetus a cell of the type required for transplantation; and d. engineering a tissue from said cells.
16. The method of Claim 15, comprising the following additional steps between said steps (c) and (d):
i. isolating an embryonic disc and/or stem cell from said embryo;
ii. injecting said disc and/or stem cell into an immune compromised animal;
iii. isolating the resulting teratoma;
iv. isolating from the teratoma a cell of the type required for transplantation; wherein said teratoma cell is used to engineer said immune compatible tissue.
i. isolating an embryonic disc and/or stem cell from said embryo;
ii. injecting said disc and/or stem cell into an immune compromised animal;
iii. isolating the resulting teratoma;
iv. isolating from the teratoma a cell of the type required for transplantation; wherein said teratoma cell is used to engineer said immune compatible tissue.
17. The method of Claim 15, wherein said tissue contains cells comprised of isogenic nuclear DNA and allogeneic mitochondrial DNA.
18. The method of Claim 15, wherein said tissue contains cells comprised of isogenic nuclear DNA and a mixture of allogeneic and isogenic mitochondrial DNA.
19. The method of Claim 15, wherein said tissue is selected from the group consisting of smooth muscle, skeletal muscle, cardiac muscle, skin, kidney and nervous tissue.
20. A method of providing a patient in need of a transplant with an immune-compatible transplant, comprising:
a. obtaining a donor cell from said patient;
b. transferring the nucleus from said cell into a recipient oocyte or other suitable recipient cell to generate an embryo;
c. isolating an embryonic disc and/or stem cell from said embryo;
d. injecting said disc and/or stem cell into an immune compromised animal in order to form a teratoma;
e. isolating the resulting teratoma;
f. isolating a cell of the type required for transplantation from the teratoma;
g. engineering a tissue from said cells; and h. transplanting said engineered tissue into said patient.
a. obtaining a donor cell from said patient;
b. transferring the nucleus from said cell into a recipient oocyte or other suitable recipient cell to generate an embryo;
c. isolating an embryonic disc and/or stem cell from said embryo;
d. injecting said disc and/or stem cell into an immune compromised animal in order to form a teratoma;
e. isolating the resulting teratoma;
f. isolating a cell of the type required for transplantation from the teratoma;
g. engineering a tissue from said cells; and h. transplanting said engineered tissue into said patient.
21. The method of Claim 20, wherein said immune compromised animal is a skid or nude mouse.
22. The method of Claim 20, wherein the donor cell obtained from said intended transplant recipient is a fibroblast.
23. The method of Claim 20, wherein said engineered tissue is selected from the group consisting of smooth muscle, skeletal muscle, cardiac muscle, skin, kidney and nervous tissue.
24. The method of Claim 20, wherein said engineered tissue comprises cells having isogenic nuclear DNA and allogeneic mitochondrial DNA.
25. The tissue engineered by the method of Claim 20.
26. An isolated tissue generated by the method of Claim 20.
27. The method of Claim 1, wherein said animal is an ungulate.
28. The method of Claim 27, wherein said ungulate is a bovine.
29. The method of Claim 15, wherein said animal is an ungulate.
30. The method of Claim 29, wherein said ungulate is a bovine.
31. The method of Claim 16, wherein said animal is an ungulate.
32. The method of Claim 31, wherein said ungulate is a bovine.
33. The method of Claim 20, wherein said intended transplant recipient is a human.
34. The method of Claim 16, wherein said patient is a human.
35. The method of Claim 16, wherein said donor cell is genetically altered prior to nuclear transfer.
36. The method of Claim 35, wherein said genetic alteration comprises the transfection of at least one heterologous gene.
37. The method of Claim 35, wherein said genetic alteration comprises the disruption of at least one native gene.
38. An animal containing at least one teratoma produced from a cloned cell.
39. The animal of Claim 38, wherein said animal is an ungulate.
40. The animal of Claim 39, wherein said ungulate is a bovine.
41. The animal of Claim 38, wherein said at least one teratoma is located in the paralumbar fascia.
42. The animal of Claim 38, wherein said teratoma is not rejected by the animal's immune system.
43. The animal of Claim 42, wherein said teratoma comprises cloned cells having isogenic nuclear DNA and allogeneic mitochondrial DNA.
44. A teratoma isolated from the animal of Claim 38.
45. The teratoma of Claim 44, wherein the teratoma contains cells from all three germ layers.
46. The teratoma of Claim 44, wherein said teratoma is derived from a cloned ungulate cell.
47. The teratoma of Claim 46, wherein said teratoma is derived from a cloned bovine cell.
48. The teratoma of Claim 48, wherein said teratoma comprises cloned cells having isogenic nuclear DNA and allogeneic mitochondrial DNA, or a mixture of allogeneic and isogenic mitochondrial DNA.
49. A stable graft comprised of isogenic nuclear DNA and allogeneic mitochondrial DNA.
50. The graft of Claim 49, wherein the cells of said graft are made by nuclear transfer of an isogenic somatic cell into an allogeneic recipient cell.
51. The graft of Claim 49, wherein said tissue is selected from the group consisting of kidney, cardiac muscle and skeletal muscle.
52. A method of identifying mitochondrial histocompatibility antigens using cross-species nuclear transfer, comprising:
a. obtaining cells from a donor mammal;
b. transferring nuclei from said donor mammal into at least two recipient oocytes or other suitable recipient cells of a mammalian species other than said nuclear donor to generate embryos, wherein said at least two recipient cells are allogeneic with regard to mitochondrial DNA;
c. isolating an embryo having at least one cell, an embryonic disc and/or stem cell from said embryo;
d. injecting said embryo, disc and/or stem cells separately back into said donor mammal as to generate a specific panel of antibodies and/or lymphocytes;
and e. comparing panels of antibodies and/or lymphocytes generated in response to said allogeneic mitochondrial backgrounds in order to identify mitochondrial antigens and/or epitopes that are recognized by the immune system of said donor mammal.
a. obtaining cells from a donor mammal;
b. transferring nuclei from said donor mammal into at least two recipient oocytes or other suitable recipient cells of a mammalian species other than said nuclear donor to generate embryos, wherein said at least two recipient cells are allogeneic with regard to mitochondrial DNA;
c. isolating an embryo having at least one cell, an embryonic disc and/or stem cell from said embryo;
d. injecting said embryo, disc and/or stem cells separately back into said donor mammal as to generate a specific panel of antibodies and/or lymphocytes;
and e. comparing panels of antibodies and/or lymphocytes generated in response to said allogeneic mitochondrial backgrounds in order to identify mitochondrial antigens and/or epitopes that are recognized by the immune system of said donor mammal.
53. The method of claim 52, wherein said embryo, disc and/or stem cells are injected into separate mammals which are isogenic to the nuclear donor with respect to both nuclear and mitochondrial DNA.
54. Antibodies specific for the mitochondrial antigens identified in the method of Claim 52.
55. Lymphocytes specific for the mitochondrial antigens identified in the method of Claim 52.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15235499P | 1999-09-07 | 1999-09-07 | |
US60/152,354 | 1999-09-07 | ||
US15510799P | 1999-09-22 | 1999-09-22 | |
US60/155,107 | 1999-09-22 | ||
PCT/US2000/024398 WO2001018193A1 (en) | 1999-09-07 | 2000-09-06 | Method for generating immune-compatible cells and tissues using nuclear transfer techniques |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2383776A1 true CA2383776A1 (en) | 2001-03-15 |
Family
ID=26849488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002383776A Abandoned CA2383776A1 (en) | 1999-09-07 | 2000-09-06 | Method for generating immune-compatible cells and tissues using nuclear transfer techniques |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1214403A4 (en) |
JP (1) | JP2003509028A (en) |
CN (1) | CN1376196A (en) |
AU (2) | AU783162B2 (en) |
BR (1) | BR0011905A (en) |
CA (1) | CA2383776A1 (en) |
IL (1) | IL148418A0 (en) |
MX (1) | MXPA02002444A (en) |
NZ (1) | NZ536786A (en) |
WO (1) | WO2001018193A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2383790C (en) * | 1999-09-07 | 2016-11-22 | Advanced Cell Technology, Inc. | Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells |
US6525242B1 (en) | 1999-11-02 | 2003-02-25 | The University Of Connecticut | Propagation of human hepatocytes in non-human mammals |
WO2001059076A2 (en) * | 2000-02-09 | 2001-08-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Premeiotic and postmeiotic origin of teratomas: isolated teratoma stem cells for therapeutic uses |
AU2003233679A1 (en) * | 2002-05-23 | 2003-12-12 | Advanced Cell Technology, Inc. | Generation of histocompatible tissues using nuclear transplantation |
JP5888852B2 (en) * | 2010-12-08 | 2016-03-22 | 学校法人近畿大学 | Cell production using immunodeficient animals |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5453366A (en) * | 1990-07-26 | 1995-09-26 | Sims; Michele M. | Method of cloning bovine embryos |
US5523226A (en) * | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
WO1998007841A1 (en) * | 1996-08-19 | 1998-02-26 | University Of Massachusetts | Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
GB9809178D0 (en) * | 1998-04-29 | 1998-07-01 | Univ Edinburgh | Nuclear reprogramming of somatic cells |
CA2334953A1 (en) * | 1999-06-30 | 2001-01-04 | Woo-Suk Hwang | Method for producing human cloned embryos by employing inter-species nuclear transplantation technique |
CA2383790C (en) * | 1999-09-07 | 2016-11-22 | Advanced Cell Technology, Inc. | Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells |
JP2003525031A (en) * | 1999-09-14 | 2003-08-26 | ユニバシティ オブ マサチューセッツ、ア パブリック インスチチユーション オブ ハイアー エデュケイション オブ ザ コモンウエルス オブ マサチューセッツ、アズ リプリゼンテッド バイ イッツ アマースト キャンパス | Method for enhancing embryo development by genetically modifying embryonic cells or stem-like cell lines and donor cells produced by hybrid nuclear transfer or tissue culture conditions |
AU782385B2 (en) * | 1999-10-15 | 2005-07-21 | Advanced Cell Technology, Inc. | Methods of producing differentiated progenitor cells and lineage-defective embryonic stem cells |
-
2000
- 2000-09-06 CA CA002383776A patent/CA2383776A1/en not_active Abandoned
- 2000-09-06 EP EP00964946A patent/EP1214403A4/en not_active Withdrawn
- 2000-09-06 IL IL14841800A patent/IL148418A0/en unknown
- 2000-09-06 AU AU75755/00A patent/AU783162B2/en not_active Expired
- 2000-09-06 NZ NZ536786A patent/NZ536786A/en not_active IP Right Cessation
- 2000-09-06 CN CN00813394A patent/CN1376196A/en active Pending
- 2000-09-06 BR BR0011905-9A patent/BR0011905A/en not_active Application Discontinuation
- 2000-09-06 WO PCT/US2000/024398 patent/WO2001018193A1/en active IP Right Grant
- 2000-09-06 JP JP2001522404A patent/JP2003509028A/en active Pending
- 2000-09-06 MX MXPA02002444A patent/MXPA02002444A/en active IP Right Grant
-
2008
- 2008-12-22 AU AU2008261167A patent/AU2008261167A1/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
NZ536786A (en) | 2006-09-29 |
MXPA02002444A (en) | 2004-07-16 |
IL148418A0 (en) | 2002-09-12 |
AU783162B2 (en) | 2005-09-29 |
BR0011905A (en) | 2003-07-08 |
JP2003509028A (en) | 2003-03-11 |
CN1376196A (en) | 2002-10-23 |
EP1214403A1 (en) | 2002-06-19 |
AU2008261167A1 (en) | 2009-01-15 |
AU7575500A (en) | 2001-04-10 |
WO2001018193A1 (en) | 2001-03-15 |
EP1214403A4 (en) | 2005-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120246746A1 (en) | Method for Generating Immune-Compatible Cells and Tissues Using Nuclear Transfer Techniques | |
US20220104467A1 (en) | Genetically modified cells, tissues, and organs for treating disease | |
Wu et al. | Interspecies chimerism with mammalian pluripotent stem cells | |
AU2017285224B2 (en) | Genetically modified cells, tissues, and organs for treating disease | |
Kita et al. | Production of functional spermatids from mouse germline stem cells in ectopically reconstituted seminiferous tubules | |
US20080003560A1 (en) | Tailor-made pluripotent stem cell and use of the same | |
JP4814226B2 (en) | Preparation method of organ for transplantation | |
JP2001523468A (en) | Transfection and transfer of male germ cells for production of transgenic species | |
US6808704B1 (en) | Method for generating immune-compatible cells and tissues using nuclear transfer techniques | |
Sackett et al. | Modulation of human allogeneic and syngeneic pluripotent stem cells and immunological implications for transplantation | |
JP2019502400A (en) | Compositions and methods for preparing chimeric embryonic auxiliary organs | |
AU2008261167A1 (en) | Method for generating immune-compatible cells and tissues using nuclear transfer techniques | |
JP2002512787A (en) | How to get stem cells | |
Sarmah et al. | Towards human organ generation using interspecies blastocyst complementation: Challenges and perspectives for therapy | |
AU2005246949A1 (en) | Method for generating immune-compatible cells and tissues using nuclear transfer techniques | |
US20090264312A1 (en) | Method for removing desired chromosome and tailor-made medical treatment utilizing the same | |
KR101270422B1 (en) | Transgenic Cats Expressing Red Fluorescence Protein and Producing Method Thereof | |
JPWO2005040361A1 (en) | Simple preparation method of stem cells and feeder cells used therefor | |
WO2002073188A9 (en) | Method for generating replacement cells and/or tissues | |
WO2002073187A1 (en) | Method for generating replacement cells and/or tissues | |
JP2012029653A (en) | Method for evaluating pluripotency of cell | |
MXPA99008933A (en) | Human embryonic germ cell line and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20120928 |